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ABSTRACT OF THE DISSERTATION
Contribution of TGF-b Signaling to the Pathogenesis of Myeloproliferative Neoplasms
by
Juo-Chin Yao
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2021
Professor Daniel C. Link, Chair

TGF-b expression is increased in most cases of myeloproliferative neoplasms (MPNs);
however, its contribution to disease pathogenesis is not well understood. Here, we explore two
specific hypotheses. First, we hypothesize that increased TGF-b signaling in mesenchymal stromal
cells contributes to the development of myelofibrosis. Second, we hypothesize that Jak2 mutated
hematopoietic stem cells (HSCs) are resistant to the growth suppressive effect of TGF-b,
conferring a fitness advantage that contributes to their expansion in MPNs and clonal
hematopoiesis.
To test the first hypothesis, we abrogated TGF-b signaling in mesenchymal
stem/progenitor cells by deleting Tgfbr2 using a doxycycline-repressible Osterix-Cre transgene
(Osx-Cre), which targets all mesenchymal lineage cells in the bone marrow. We transplanted
hematopoietic stem/progenitor cells (HSPCs) transduced with MPLW515L retrovirus or bone
marrow cells from Jak2V617F mice into irradiated wild type or Osx-Cre; Tgfbr2f/- recipients.
MPLW515L induced a rapidly fatal MPN with reticulin fibrosis in the bone marrow. A similar
hematopoietic phenotype and survival was observed in Osx-Cre; Tgfbr2f/- recipients. However,
xv

myelofibrosis, as measured by reticulin staining, collagen I and III immunofluorescent staining,
and Col3a1 and Acta2 mRNA expression, was significantly reduced in Osx-Cre; Tgfbr2f/- mice.
Likewise, in the Jak2V617F MPN model, expression of collagen I and III in the bone marrow was
significantly reduced in Osx-Cre; Tgfbr2f/- recipient mice. Surprisingly, induction of myelofibrosis
by MPLW515L was intact in Osx-Cre; Smad4f/f recipients, suggesting that SMAD4-independent
(non-canonical) TGF-b signaling mediates the myelofibrosis phenotype. Consistent with these
findings, TGF-b1 induced expression of fibrosis associated genes, Col1a1, Acta2 and Loxl1, was
intact in primary cultures of Smad4-deleted bone marrow derived mesenchymal stromal cells
(MSCs). However, treatment with a JNK inhibitor, but not inhibitors of MEK, p38, or NFkB,
abrogated the TGF-b1-induced expression of fibrosis markers in vitro, and preliminary data
suggests that treatment with a JNK inhibitor attenuates myelofibrosis induced by MPLW515L in vivo.
Together, these data show that TGF-b signaling contributes to the development of myelofibrosis
in MPN through activation of the JNK pathway in MSCs.
To test the second hypothesis, we first assessed TGF-b signaling in wild type and Jak2V617F
HSPCs. Whereas TGF-b1 induced robust Smad2/3 phosphorylation in wild type HSCs, it was
barely detectable in Jak2V617F HSCs. Interestingly, this phenotype was lost in lineage-restricted
progenitors, where TGF-b-induced Smad2/3 phosphorylation was comparable in wild type and
Jak2V617F cells. These data suggest that TGF-b signaling, at least Smad2/3 phosphorylation, is
selectively loss in Jak2V617F HSCs. Competitive repopulation assays (CRAs) were performed using
wild type and Jak2V617F HSPCs, in which Tgfbr2 was deleted to abrogate TGF-b signaling in
HSCs. CRAs comparing wild type and Tgfbr2-/- HSPCs showed that TGF-b signaling negatively
regulates repopulating activity. When competing Jak2V617F with Jak2V617F; Tgfbr2-/-, the Tgfbr2
deleted group no longer had repopulating advantage, confirming Jak2V617F is resistant to TGF-b.
xvi

As expected, Jak2V617F HSCs had a competitive repopulating advantage to wild type. However,
this fitness advantage was loss when the competitor HSPCs lack Tgfbr2. Moreover, no competitive
advantage of Jak2V617F was observed when both wild type and Jak2V617F HSCs are Tgfbr2deficient. This data suggest that TGF-b contributes to clonal expansion of Jak2V617F by inhibiting
wild type HSCs. Using cell cycle analysis and transcriptome analysis, we further showed that,
opposite to published in vitro data, TGF-b may promote cell cycle progression in a non-cell
intrinsic manner in vivo. This may contribute to the less quiescent phenotype in Jak2V617F HSCs.
Collectively, our data show that TGF-b plays an essential role in the pathogenesis of
MPNs. We identify that TGF-b signaling in mesenchymal stromal cells is required for the
development of myelofibrosis through the non-canonical JNK pathway. TGF-b signaling in
JAK2V617F HSPCs also plays a key role in the clonal expansion in MPNs. Specifically, our data
support a model in which increased local production of TGF-b by JAK2V617F hematopoietic cells
selectively inhibits wild type HSPCs, thereby promoting the expansion of JAK2V617F HSPCs.
Targeting TGF-b or JNK signaling in patients with myelofibrosis may be beneficial in the
treatment of bone marrow fibrosis. Targeting TGF-b signaling early in the course of MPN or in
persons with JAK2V617F clonal hematopoiesis may prevent or delay clonal progression.
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Chapter 1: Introduction to Myeloproliferative
Neoplasms and the TGF-b signaling
1.1 Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPNs) are chronic myeloid malignancies characterized by
overproduction of myeloid lineage cells. It can be divided into BCR-ABL+ chronic myelogenous
leukemia (CML), polycythemia vera (PV), essential thrombocytosis (ET) and primary
myelofibrosis (PMF)1. Mutations occurring in hematopoietic stem and progenitor cells (HSPCs)
altering the JAK-STAT signaling pathway are the major cause of BCR-ABL- MPNs2.

1.1.1 Classification of MPNs
The BCR-ABL- MPNs present with erythrocytosis (PV), thrombocytosis (ET) and
myelofibrosis (PMF). PV patients have elevated hemoglobin counts and elevated erythropoietin
(EPO) level in the serum. ET patients have elevated platelet counts associated with proliferation
of mature megakaryocytes. PMF patients have megakaryocyte proliferation with atypia along with
bone marrow reticulin and/or collagen fibrosis1. PV and ET patients also can progress to secondary
myelofibrosis (MF). Patients with myelofibrosis carry the worse prognosis and quality of life
among all MPNs, with most severe morbidity and greatest mortality3,4. Patients with PV and PMF
have a risk of progression to acute myeloid leukemia (AML). For PMF, 10–20% of patients may
progress to AML at 10 years. While for PV patients, the risk is 2.3% at 10 years and 7.9% at 20
years5. The chance of progressing to AML from ET is relatively unlikely.
1

1.1.2 Aberrant signaling in MPNs
More than 90% of PV patients and around 50% of ET and PMF patients carry a somatic
JAK2V617F mutation2. An additional 5-10% of ET and PMF patients have activating mutations in
the thrombopoietin receptor gene (MPLW515L/K)2. The majority of the ET and PMF patients who
are negative for JAK2 or MPL mutations carry somatic mutations in calreticulin (CALR)6 (Fig.
1.1). While mutations in JAK2 and MPL are gain-of-function point mutation, mutations in CALR
occur as +1 base-pair frameshifts in the last coding exon of CALR, resulting in the generation of
novel C-terminus6,7. These mutations are mutually exclusive and occur at the HSPC level. JAK2
belongs to the Janus Kinases family and is crucial for the downstream signaling of growth factor
receptors including erythropoietin receptor (EPOR)8, thrombopoietin receptor (TPOR or MPL)9,10
and granulocyte colony-stimulating factor receptor (G-CSFR)11. The V617F mutation locates in
the pseudokinase domain of JAK2 gene, leading to constitutive activation of the downstream
kinase domain12. Overactivation of JAK2 leads to hypersensitivity and ligand independent
activation of the growth factor receptors, contributing to proliferation and differentiation of
myeloid progenitors2. Mutations in MPL that lead to constitutive activation of the thrombopoietin
receptor are also a common cause of thrombocytosis and myelofibrosis13,14. Finally, mutations in
CALR leads to a positive charged C-terminal domain that also loses ER retention signal (KDEL).
The positive charged C-terminus promotes binding and activation of MPL6,15.
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Figure 1.1. Distribution of JAK2, MPL and CALR mutations in patients with three classical
BCR-ABL- MPNs. Figure modified from Klampfl et al6.

1.1.3 Cell of origin of MPNs
Evidence has suggested that driver mutations of MPNs arise in hematopoietic stem cells
(HSCs). It has been shown that the JAK2V617F mutation is detectable in immunophenotypically
defined HSCs (Lin- CD90+ CD34+ CD38-) and the downstream myeloid progenitors, including
common myeloid progenitors (CMPs) (Lin− CD34+ CD38+ IL-3Rα+ CD45RA−), granulocytemacrophage progenitors (GMPs) (Lin− CD34+ CD38+ IL-3Rα+ CD45RA+), and megakaryocyteerythroid progenitors (MEPs) (Lin− CD34+ CD38+ IL-3Rα− CD45RA−) in MPN patients16. More
importantly, studies have provided definitive proof that JAK2V617F mutation arises from stem cell
level by detecting the mutation in lymphoid progenitors17 and mature lymphoid cells18,19 in MPN
patients. Specifically, Delhommeau et al. has demonstrated that single cell sorted CD38- CD34+
progenitors from PV and PMF patients were able to generate both myeloid and lymphoid cells.
They confirmed the presence of JAK2V617F in both the myeloid and lymphoid generating clones,
suggesting that JAK2V617F happened in a myeloid-lymphoid multipotent progenitor/stem cell
level17. Two other studies were able to detect Jak2V617F in sorted mature lymphoid populations,
including CD19+ B cells, CD3+ T cells, from PV and PMF patients18,19. This data also suggests
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that JAK2V617F occurs at the stem cell level. CALR mutations were also demonstrated to be present
in the HSCs and progenitor populations by genotyping hematopoietic colonies from MPN patients7.
Studies using transgenic mouse models further provided evidence that only when JAK2V617F
mutation happens in HSC compartment can the cells have disease initiating ability, even JAK2V617F
multipotent progenitors lack disease propagating potential20,21. Studies tracking JAK2V617F mutant
allele burden in MPN patients have suggested difference between chronic phase MPNs (PV and
ET) to the more advanced phase MPNs (MFs). It has been reported that the expansion of the CD34+
CD38- HSC compartment was only present in MF patients but not PV and ET patients22. Another
independent study also demonstrated that JAK2V617F mutant allele burden in CD34+ HSPCs was
higher in MF patients comparing to PV and ET patients23. Surprisingly, they found that the
expansion of JAK2 mutant cells was independent of the homozygosity of JAK2V617F, suggesting
that clonal expansion of the CD34+ compartment is possibly driven by other somatic genetic
alterations24. For instance, multiple studies have shown that loss-of-function mutations of
epigenetic regulators Tet225,26 and Ezh227-29 enhance the repopulating activity of Jak2V617F diseasepropagating MPN stem cells in genetic mouse models. Studies using MPN patient-derived
xenografts have found that mobilized peripheral blood CD34+ cells from JAK2V617F-mutant
patients with PV engrafted relatively poorly30,31, while CD34+ cells from either the peripheral
blood or the spleens of patients with MF demonstrate sustained engraftment32,33.

1.1.4 Heterogeneity of MPNs
Although PV, ET and PMF patients have many shared clinical and biological features,
including activation of JAK-STAT signaling and myeloid proliferation, they also exhibit a range
of distinct clinical phenotypes. The MPN phenotype is partly determined by the specific driver
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mutation that is acquired. CALR and MPL mutations are almost always associated with an ET or
MF phenotype, but not a PV phenotype. This is, as least partly, due to activating signaling through
MPL, which is selectively expressed on HSCs and megakaryocytic lineage cells14,34-36. Therefore,
activation of this pathway leads to megakaryopoiesis and thrombocytosis phenotypes. However,
the much more common JAK2V617F mutation has a striking heterogeneity in terms of clinical
phenotypes, which is associated with PV, ET and PMF phenotypes in human and mouse
models37,38. It remains unclear why this mutation in HSCs can result in such different clinical
phenotypes. Moreover, recent studies have identified JAK2 mutations in clonal hematopoiesis in
healthy individuals39-41, indicating that even if an HSC acquires a mutation in JAK2, it may never
progress to MPN. Several studies have provided a potential explanation for JAK2V617F-associated
heterogeneity in MPN clinical phenotypes. Using genetic mouse models to control the expression
level of JAK2V617F, Tiedt et al. suggested that when the JAK2V617F allele burden is lower than that
of endogenous wild type JAK2, it could lead to ET phenotypes42. However, equal to over
expression of JAK2V617F comparing to endogenous level leads to PV like phenotypes. Downstream
signaling of JAK2, including activation of STAT1, has also been shown to affect MPN clinical
phenotypes. While increased STAT1 activation leads to ET-like phenotypes, downregulation of
STAT1 activity leads to PV-like phenotypes43. The presence of TET2 mutation and the order in
which JAK2 and TET2 mutations are acquired may also affect clinical phenotype44.

1.1.5 Treatment of MPNs
Current drug therapy in PV, ET, or PMF is neither curative nor capable of prolonging life
or preventing disease progression45. The only curative therapy for MPN patients is allogeneic stem
cell transplant (ASCT)46. However, due to the toxicity associated with the transplantation
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procedure, ASCT is currently restricted to only a minority of younger patients with advanced
MPNs47. Treatments for PV and ET are primarily for alleviating symptoms and prevention of
thrombosis. The usage of phlebotomy in patients with PV to keep the hematocrit normal has highly
improved the median survival from <2 years to 14 years and is currently indicated for all PV
patients48. In addition, patients with PV and ET might also require aspirin, anticoagulant and/or
cytoreductive drugs, for lowering their risk of thrombosis or bleeding. The current first line
cytoreductive drug choice for PV and ET is hydroxyurea48, which is an inhibitor of ribonucleotide
reductase, an enzyme that mediates the synthesis of deoxyribonucleotides49. In patients who are
resistant or do not tolerate hydroxyurea therapy, interferon-a or busulfan are used as second-line
drugs of choice48. For PMF patients, the only treatment that can cure or even prolong life is ASCT.
Drug treatments are only available for relief of symptoms, including splenomegaly, anemia or
bone pain48. With the mutation in JAK2 being identified in majority of MPN patients, ruxolitinib,
the tyrosine kinase inhibitor for JAK1/JAK2, has been developed and approved by the US Food
and Drug Agency and European Medicines Agency for the treatment of intermediate and high risk
MF and as second line therapy for PV patients resistant or intolerant to hydroxyurea50. Ruxolitinib
has been shown to improve hematocrit and reduce spleen volume in PV patients51-53 and
demonstrated efficacy in spleen volume reduction and symptom burden reduction with a moderate
improvement in overall survival in PMF54-59. However, there is very limited impact to promote
complete hematological remission, reduce the mutant allele burden or reverse bone marrow
fibrosis50. Transformation to acute myeloid leukemia can still occur50. Therefore, the development
of more effective treatments for these diseases is still an urgent need.
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1.1.6 Mouse models of MPNs
In order to better study the pathogenesis of MPNs, numerous different mouse models have
been developed. Before the identification of driver mutations causing MPN, TPO overexpression
using retrovirus were the first model used to study myelofibrosis. TPO overexpression leads to
thrombocytosis, leukocytosis, anemia and splenomegaly with marked megakaryopoiesis in the
spleen and reticulin fibrosis and osteosclerosis in the bone marrow60,61. It has also been shown that
transplantation of normal bone marrow could reverse both the hematopoietic phenotypes and the
myelofibrosis and osteosclerosis phenotypes induced by TPO62. Later, transgenic mice
overexpressing murine TPO were developed and these mice had similar phenotypes as the
retroviral overexpression models63. However, no abnormal production or mutation of TPO has
ever been identified in patients with MPNs64, raising concerns about the relevance of using Tpo
overexpression to model human MPNs.
After the discovery of JAK2V617F as the most common mutation in patients with MPNs in
2005, multiple retroviral models expressing the mutation were developed65-69. These models all
developed more PV-like diseases with marked erythrocytosis, leukocytosis, and splenomegaly.
Secondary myelofibrosis was also detected in these mice 3-4 months after transplantation. These
studies provided evidence that Jak2V617F is sufficient to induce MPN-like disease in mice.
Following the retroviral models, three groups have generated transgenic mice carrying murine70
or human42,71 JAK2V617F in 2008 in order to better characterize the role of this mutation in a steady
state condition. Different promoters were designed to drive the expression of the mutation and
these models provided more variable phenotypes comparing to the previous retroviral models.
Major conclusion drew from these transgenic mouse models were that the expression level of
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JAK2V617F mutation influenced the phenotypes it derived. Lower expression led to more ET-like
phenotypes while higher expression gave rise to a more PV-like disease.
Limitations of the retroviral and transgenic Jak2V617F models are the non-physiologic high
level of Jak2V617F achieved in the retroviral model and the lack to tissue-specific expression of
Jak2V617F achieved in both models. To address this problem, four groups independently generated
knock-in models of murine20,72,73 or human74 JAK2V617F. Akada et al. utilized an Mx1-Cre inducible
model to express Jak2V617F in the hematopoietic compartment72. These mice developed a severe
PV-like syndrome with leukocytosis, erythrocytosis, thrombocytosis and splenomegaly.
Progression to myelofibrosis was also observed in this model. Among the four models, this was
the only one in which homozygous Jak2V617F mice could be generated. Homozygous Jak2V617F
mice had a more severe PV-like disease with higher white blood cell (WBC) and red blood cell
(RBC) counts, increased splenomegaly, and bone marrow fibrosis compared to heterozygous
Jak2V617F mice. In the other three models, the knock-in mutation generated a non-functional or
functionally altered Jak2 allele prior to activation of Cre-recombinase induced recombination and
expression of Jak2V617F. Thus, since homozygous Jak2-/- mice are embryonic lethal, homozygous
mutant mice could not be generated in these three models. Marty et al. expressed germline
constitutive Jak2V617F in their knock-in model generating a PV-like phenotype with myelofibrosis
at 9 months of age73. Mullally et al. generated a conditional knock-in allele in which excision is
mediated by E2a-Cre during embryogenesis and they also observed a PV-like phenotype
characterized by leukocytosis, erythrocytosis and splenomegaly20. However, there was minimal
effect on platelet counts and no fibrosis developed, even in aged (>6 months) mice20. These mice
also have a significant reduced survival comparing to other models (median 146 days). Finally, Li
et al. knocked-in human JAK2V617F into the murine Jak2 locus and utilized Mx1-Cre-mediated
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recombination to induce human JAK2V617F expression74. In contrast to the other models, these mice
developed a more ET-like disease, with only modest thrombosis and erythrocytosis, and no
significant changes in WBC counts or splenomegaly. Whether this is due to differences in
signaling of human and murine JAK2V617F is unknown.
In 2006, MPLW515L and MPLW515K mutations were identified in 5-10% and 1% of JAK2V617F
negative patients with PMF or ET respectively13,14. Retroviral transduction model of MPLW515L
were then being developed to access the effect of MPL mutation on MPN disease14. These mice
developed a more ET-like disorder with marked thrombocytosis and leukocytosis, with little effect
on RBCs. Splenomegaly and reticulin fibrosis were also observed.
After the identification of CALR mutations in ET and PMF patients in 20136,7, retroviral
transduction models of the most common CALR mutations, CALRdel5236,75 and CALRins536, were
generated in 2016. Two independent groups showed that retroviral expression of CALRdel52
results in the development of thrombocytosis with minimal effect on WBC and RBC. However,
the model by Elf et al. did not developed fibrosis while Marty et al. observed reticulin fibrosis six
months after transplantation. Of note, in these two studies, the development of fibrosis correlated
with the degree of thrombocytosis. A transgenic model of human CALRdel52 was also generated
the same year and these mice developed a similar ET-like disease as the retroviral models, with
thrombocytosis but no changes in WBC, RBC or fibrosis76.
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1.2 Hematopoietic Niche of MPNs
The proliferation, self-renewal, and trafficking of HSCs are known to be dependent on
signals generated by the stromal compartments in the bone marrow microenvironment. Stromal
cells are organized into niches that support specific subsets of hematopoietic progenitors. There
have been considerable studies focusing on bone marrow stromal cell populations and the signals
they generate that contribute to HSC maintenance as well as the development of hematopoietic
malignancies, including MPNs.

1.2.1 Normal hematopoietic niches in the bone marrow
The stem cell niche was originally defined by localizing HSCs in the bone marrow and
then identifying and characterizing the nearby stromal cells. Initial studies transplanted labeled
HSC-enriched populations into irradiated recipient mice have shown that HSCs tended to localize
to the endosteal regions in the bone marrow, implicating osteolineage cells in the stem cell
niche77,78. However, irradiation is known to induce significant alterations in the bone marrow
microenvironment, including a loss of endothelial cells79 and an expansion of osteoblasts80. With
the discovery of signaling lymphocyte activation molecule family markers (SLAM family
markers) for HSCs81, it became possible to image stem cell localization in steady-state conditions.
Using combinations of different HSC markers, numerous studies have provided evidence that
HSCs localized near the blood vessels in the bone marrow81-84. More recently, new genetic markers
for HSCs have been identified, including Ctnnal185 and Hoxb586, and transgenic reporter mice
have been utilized for imaging HSC localization. Studies using the HSC reporter mice also
suggested that the majority of HSCs localized to perivascular regions and distributed throughout
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the bone marrow under steady-state conditions85,86. However, one recent study using novel
multicolor imaging of thick full-bone sections demonstrated that the localizations of HSCs
reflected the relative abundance of bone marrow niche populations rather than active enrichment87.
They comprehensively quantified HSC localization with total nine different bone marrow
components. Consistent with previous reports, HSCs were found to be proximal to sinusoids,
CXCL12-abundant reticular (CAR) cells, megakaryocytes but not bone, adipocytes, peri/arteriolar or Schwann cells. Importantly and surprisingly, HSCs localizations were not different
from that of computationally placed random dots, suggesting that the distribution of HSCs is
primarily driven by the abundance of niche components in the bone marrow.
The perivascular space in the bone marrow is comprised of a diverse population of stromal
cells, including perivascular mesenchymal stromal cells (MSCs) that have been defined as
CXCL12-abundant reticular (CAR) cells83,88, leptin-receptor+ (Lepr+) stromal cells89, or nestinGFP+ (Nes-GFP+) stromal cells84. These overlapping MSC populations express high levels of key
niche factors including CXCL12 and stem cell factor (SCF) and have been implicated in HSC
maintenance88-92. CXCL12 was the first HSC niche factor that was characterized in the bone
marrow83,88,93. CAR cells were originally described by Nagasawa and colleagues using Cxcl12
knock-in reporter mice83. Cxcl12 expressing CAR cells are mainly perivascular stromal cells that
are in close physical proximity to sinusoids. SCF is the ligand for KIT and has been shown as
another important niche factor required for HSC maintenance94,95. Using Scf knock-in reporter
mice, Morrison and colleagues showed that Lepr+ perivascular stromal cells were the major source
of Scf and that Scf from Lepr+ cells is required for HSCs89. In addition, Frenette and colleagues
identified that Nestin-GFP+ stromal cells as another MSC population that also express Cxcl12 and
Scf84,92. While CAR cells and Lepr+ cells represent approximately 0.3% of total bone marrow cells
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that are mainly perisinusoidal, Nestin-GFP+ cells consist only 0.08% of total bone marrow and are
both perisinusoidal and periarteriolar96. The perivascular niche also contains several other cell
types that have been implicated in HSC regulation, including sinusoidal and arteriolar endothelial
cells79, NG2+ arteriolar pericytes84, sympathetic nerves97,98, non-myelinating Schwann cells99, and
megakaryocytes100,101. The role of osteolineage cells in HSC maintenance remains controversial.
There is evidence suggests that immature osteolineage cells instead of the mature osteoblasts may
contribute to the regulation of HSCs78. Thus, the HSC niche is comprised of a heterogeneous
population of stromal cells, each of which may generate signals that collectively contribute to HSC
maintenance (Fig. 1.2).

Figure 1.2. The hematopoietic stem cell niche. Most HSCs localize adjacent to sinusoids, where they
are in close contact with LEPR+/CAR cells and endothelial cells, both known to be important sources of
key niche factors CXCL12 and SCF. A smaller percentage of HSCs localize near the arterioles, which are
also associated with LEPR+/CAR cells, as well as NG2+ periarteriolar pericytes. Megakaryocytes,
macrophages, nerve fibers, Schwann cells associated with nerve fibers, and osteoclasts are also shown to
regulate HSC maintenance. Osteoblasts can promote the maintenance of a subset of early lymphoid
progenitors, but other lymphoid progenitors reside in sinusoidal niches, where they depend on CXCL12
synthesized by LEPR+/CAR cells. Figure adopted from Crane et al96.
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1.2.2 Altered stem cell niche in hematopoietic malignancies
Alterations in the bone marrow niche have been reported in most human hematopoietic
malignancies (reviewed in102). In acute lymphoblastic leukemia (ALL), expression of key
lymphoid trophic factors, including CXCL12, Interleukin-7, and B-cell activating factor are
reduced in the stromal compartments103,104. Studies also showed that MSCs derived from the bone
marrow of children with ALL have increased adipogenic capacity but reduced ability to support
hematopoietic progenitor proliferations105. In chronic myelogenous leukemia (CML), there is a
marked increase in bone marrow vasculature caused by increased stromal cell expression of
placental growth factor106. In myelodysplastic syndrome (MDS), in contrast to ALL, CXCL12
expression is increased107,108. This is possibly due to the expansion of CXCL12-positive CD271+
perivascular stromal cells107. It has been reported that 38% of cases of MDS or acute myeloid
leukemia (AML) have increased b-catenin signaling and b-catenin nuclear accumulation in
osteoblasts109. Studies of bone marrow MSCs from MDS or AML patients have shown reduced
osteogenic differentiation as well as premature senescence110,111. Lastly, bone marrow derived
MSCs from patients with MDS or AML have increased expression of key niche factors that may
selectively support the growth of the malignant clone over normal hematopoietic cells112.

1.2.3 The malignant niches of MPNs—megakaryocyte dependent
There is considerable evidence suggesting that the bone marrow microenvironment
contributes to the development of myelofibrosis in MPNs. Excessive numbers of megakaryocytes
with an abnormal nuclear/cytoplasmic ratio and a reduced polyploid state is identified in PMF
patients. Studies have shown using in vitro differentiation assays that CD34+ HSPCs from PMF
patients had extensive megakaryocytic differentiation and expansion abilities compared to healthy
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controls. These PMF derived megakaryocytes were immature and showed delayed apoptosis
owing to increased expression of the anti-apoptotic factor Bcl-xL113. Of note, Wen et al. has
reported that treatment with an inhibitor targeting the aurora kinase A (AURKA), which induces
megakaryocyte differentiation and polyploidization, reduced bone marrow fibrosis in both
MPLW515L and JAK2V617F induced MPN in mice114. Elevated inflammatory cytokines, including
transforming growth factor-beta (TGF-b) and platelet derived growth factor (PDGF), are increased
in MPN patients, and megakaryocyte and monocytes were shown to be the major sources of these
cytokines115-117. As discussed below, studies suggest that the elevated cytokine production from
the malignant clones acts on the stromal compartments in the bone marrow to promote
myelofibrosis.

1.2.4 The malignant niches of MPNs—Role of TGF-b signaling
Numerous studies have demonstrated that elevated TGF-b signaling in MPN contributes
to the development of myelofibrosis in MPNs. TGF-b is found to be elevated and corelated with
the development of fibrosis in wild type mice treated with TPO118. Chagraoui et al. used TPO
retroviral overexpression to induce myelofibrosis in mice, and they showed that when
overexpressing TPO in Tgfb1 deleted hematopoietic cells, mice no longer developed
myelofibrosis119. Using Gata2low mice, another mouse model of myelofibrosis, Zingariello et al.
demonstrated that treatment with the TGFbR1 inhibitor SB431542 reduced fibrosis in the bone
marrow120. Surprisingly, they also found improvement in the hematopoietic phenotypes with
reduced splenomegaly and normalized c-Kit+ progenitor cell numbers. This group further used
primary human samples from JAK2 mutant MPN patients to show that treatment with SB431542
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also increased the colony forming ability of JAK2 mutant HPSCs121. Moreover, another study
showed that treatment with another TGFbR1 inhibitor galunisertib significantly reduced fibrosis
in the MPLW515L retroviral mouse model and JAK2V617F transgenic mouse model of MPNs122.
However, hematopoietic phenotypes, including splenomegaly and myeloproliferation, were not
improved after galunisertib treatment. Currently, there is a novel TGF-b1 & TGF- b3 inhibitor,
AVID200, being tested in a phase I/Ib clinical trial to treat myelofibrosis (NCT03895112).

1.2.4 The malignant niches of MPNs—TGF-b-independent
Decker et al. reported that deletion of PDGF receptor alpha (Pdgfra) in the stromal
compartment ameliorated bone marrow fibrosis in the TPO overexpression mouse model of
MPN123. In addition, treatment with imatinib, which blocks PDGFRa activation, also improved
the fibrosis phonotype in mice. On the other hand, another group showed, using in vitro culture of
mouse Gli1+ mesenchymal stromal cells, that treatment with Cxcl4 led to increased alpha smooth
muscle actin (a-SMA) expression, a myofibroblast marker124. By utilizing a co-culture system of
Cxcl4-/- c-Kit+ HSPCs with Gli1+ stromal cells, they also demonstrated that losing Cxcl4 in HSPCs
could prevent stromal cells from differentiating into myofibroblasts. Recently, this group further
showed that MPN patients have elevated CXCL4 staining in their bone marrow which correlates
with myelofibrosis grades125. Using TPO, MPLW515L and JAK2V617F retroviral MPN mouse models,
they showed that deletion of Cxcl4 in hematopoietic cells alleviated both myeloproliferative and
fibrosis phenotypes of MPNs. Furthermore, the authors suggested that this phenotype is IL-6dependent. Absence of Il6 could also ameliorate bone marrow fibrosis induced by TPO overexpression in mice.
15

1.2.5 The malignant niches of MPNs—changes in osteoblasts and osteoclasts
Alterations in bone metabolism also has been identified in patients with MPNs. A
nationwide study in Denmark found that patients with ET, PV and CML had increased risk of
osteoporotic fractures compared to the general population126. Interestingly, the same research
group also found no significant change in bone mineral density and microarchitecture in PV, ET127
and MF128 (both primary and secondary) patients, suggesting that the fractures were not due to
secondary osteoporosis. In a Jak2V617F knock-in mouse model of MPN, the authors identified
decreased trabecular bone mass and osteoblasts numbers with normal osteoclast numbers and
activity129. Nevertheless, another study showed that JAK2V617F heterozygous mutated monocytes
from MPN patients have increased osteoclast-formation ability comparing to JAK2 wild type MPN
monocytes and monocytes from normal donors130. However, whether these osteoclasts have
normal or altered function is unknown. The mechanisms behind the increased risk of fracture in
MPN patients remains unknown, but chronic inflammation, specifically elevated IL-6, is proposed
to be a potential cause131-133.
On the other hand, diffused osteosclerosis is one of the typical histology findings in severe
cases of myelofibrosis134-136. Two studies provided evidence that myelofibrosis patients have
increased bone volume and bone mineral density when comparing to healthy controls137,138. A
histomorphometric study also showed that patients with myelofibrosis have significantly more
bone tissue compared to other types of MPN patients139. Radiological images of patients with
myelofibrosis provided evidence that osteosclerosis is most commonly found in the metaphyseal
ends of long bones140,141. A study using a BCR-ABL driven CML mouse model demonstrated that
MPN myeloid cells stimulate MSCs to generate osteoblasts142. Increased inflammatory signaling,
including TGF-b, and decreased niche factors, including CXCL12 and SCF, are found in these
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expanded osteoblasts. Using in vitro co-culture assays following by bone marrow transplantation,
they showed that the MPN-expanded osteoblasts have altered function in supporting normal HSCs,
while mutant HSCs are resistant to the effect of these altered osteoblasts. One study suggested the
increased production of osteoprotegerin (OPG) by endothelial cells may contribute to the
development of osteosclerosis, since OPG inhibits osteoclast development143. Using OPG deficient
mice as either donors or recipients, Chagraoui et al. showed that the osteosclerosis phenotype
induced by TPO overexpression is dependent on OPG produced by stromal but not hematopoietic
compartments144.

1.2.6 The malignant niches of MPNs—changes in neurological cells
There is evidence that malignant hematopoietic stem cell populations in MPNs may
generate signals that alter stromal cell function. Arrant et al. reported that interleukin-1b
production by HSCs carrying the JAK2V617F mutation cause neural damage and Schwann cell
apoptosis145. Importantly, previous studies have shown that sympathetic nerves and Schwann cells
generate signals that regulate mesenchymal stromal cells in the bone marrow97,99. Indeed, a loss
of Nestin-GFP+ stromal cells and a decrease in bone marrow Cxcl12 was observed in Jak2V617F
mice. In the same study, a Jak2V617F MPN murine model was used to demonstrate that β3-agonist
exposure, which restored the sympathetic regulation of Nestin+ MSC, abrogated MPN progression
and led to a reduction in disease-associated HSC. Recently, a phase II clinical trial of a β-3
sympathomimetic agonist, mirabegron, on Jak2V617F MPNs was done in Switzerland. Although
Jak2 mutant allele burden was not decreased, a modest but significant reduction of reticulin
fibrosis was achieved146.
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1.2.7 The malignant niches of MPNs—changes in endothelial cells
The vascular niche has also been shown to be altered in MPNs. A study of 115 MPN
patients demonstrated significant increases in micro vessel density (MVD) in PMF patients
compared to PV and ET patients147. Post-PV and post-ET myelofibrosis patients also had elevated
MVD. They further showed that MVD was highly correlated with JAK2V617F mutational burden.
These changes are possibly occurring as a consequence of increased vascular endothelial growth
factor (VEGF) expression in the bone marrow of these patients148.

1.2.8 The malignant niches of MPNs—mutations in the niche
There also is evidence suggesting that mutations in stromal cells, including deletion of
Rarg (retinoic acid receptor γ)149, Rb1 (retinoblastoma 1)150, Mib1 (an essential component for
Notch ligand endocytosis)151, or the DNA-binding domain of Rbpj (RBP-Jk, which also is required
for Notch signaling)152, could drive the development of a myeloproliferative-like disorder in mice.
These are important proof-of-principle experiments that suggest the disruption of Notch signaling
and certain other signaling pathways in the stromal compartments can contribute to the
development of myeloid malignancies. However, their direct relevance to human hematopoietic
malignancies is uncertain, since germline mutations of these genes, except for RB1, have not been
linked to human myeloid malignancies.
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1.2.9 The cell of origin of myelofibrosis
The cell of origin of the fibrotic tissue in MPNs remains controversial. Different studies
have provided evidence that mesenchymal stromal cells, monocyte derived fibrocyte or endothelial
cells could be the cell of origin responsible for bone marrow fibrosis.
Two papers using transgenic tdTomato reporter mice suggested that Lepr+ mesenchymal
stromal cells123 or Gli1+ mesenchymal stromal cells124 are the fibrogenic cells in the bone marrow.
Decker et al. used TPO overexpression to induce myelofibrosis in the Lepr-tdTomato reporter mice
and showed that the tdTomato labeled Lepr+ mesenchymal stromal cells have a fibrotic
morphology in the bone marrow123. Schneider et al. transplanted TPO or JAK2V617F transduced
HSPCs into Gli1-tdTomato reporter mice and showed that tdTomato labeled Gli1+ mesenchymal
stromal cells are the fibrotic cells in the marrow. They further claimed that treatment with GANT61,
which is a small-molecule compound inhibitor of Gli proteins, ameliorates Jak2V617F induced
myelofibrosis124.
On the other hand, another set of studies suggested that monocyte derived fibrocytes are
the fibrogenic cells in myelofibrosis. Fibrocytes were originally identified in 1994 as circulating
hematopoietic origin cells with fibroblast-like properties, and known to be involved in wound
healing and tissue repair153,154. Evidence also suggested that fibrocytes contribute to the induction
of fibrosis in lung155, kidney156 and heart157. Verstovsek et al. performed immunofluorescent
staining on bone marrow biopsy specimens from myelofibrosis patients and found significantly
increased fibrocytes, defined as cells co-staining with a hematopoietic marker CD45 and fibrosis
markers CD90 and procollagen-I158. Treatment with pentraxin protein serum amyloid P (SAP)
component (pentraxin-2), a putative fibrocyte inhibitor, in the MPLW515L MPN mouse model
prevented the development of myelofibrosis. Another group from Japan showed that treatment
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with the TPO receptor agonist romiplostim (Rom) induced fibrocyte differentiation in vitro and
myelofibrosis in vivo159. Furthermore, they claimed that fibrogenic cells have a monocytemacrophage origin since elimination of macrophages using clodronate liposomes reversed the
fibrosis phenotype in the Rom induced myelofibrosis mouse model.
Finally, there has been evidence implicating endothelial cells in the development of
myelofibrosis. Several studies have shown that endothelial cells are altered160,161 or even harbor
Jak2V617F mutations in MPN patients162. Under inflammatory conditions, including TGF-b
stimulation163,164, endothelial cells can undergo a biological process known as endothelial-tomesenchymal transition (EndMT) and may contribute to the development of fibrosis in solid
organs, including heart165, kidney166. A recent study demonstrated that EndMT happens in PMF
patients. By using an in vitro culture system of endothelial progenitor cells from healthy donor and
PMF patients, they showed that stimulation with inflammatory cytokines TGF-b, IL-1b and TNFa decreased endothelial markers, VE-cadherin and claudin-5, expression and increased
mesenchymal markers, Snail, N-cadherin, fibronectin, and CD44167. They further suggested that
inflammatory cytokines that are released from a-granules of both megakaryocytes and platelets
triggered EndMT, while inhibition of TGF-b signaling by inhibitor of TGF-b receptor I and II
prevented EndMT.
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1.3 The TGF-b Signaling Pathways
1.3.1 TGF-b ligand
There are more than 30 pleiotropic ligands that belong to the Transforming growth factorβ (TGF-β) superfamily, including TGF-βs, bone morphogenetic proteins (BMPs), growth
differentiation factors (GDFs), activins, inhibins, nodal and anti-mullerian hormone (AMH)168.
Among these, TGF-bs are particularly known to be important factors in the hematopoietic niche
and the regulation of hematopoietic stem cells169-171. Three highly homologous isoforms of TGFβs exist in humans: TGF-β1, TGF-β2 and TGF-β3. They share the receptor complexes and signal
in similar ways, but TGF-β1 is thought to be the dominant isoform regulating hematopoiesis172.
Each TGF-β ligand is synthesized as a precursor, which forms a homodimer that interacts with
latency-associated peptide (LAP) and a latent TGF-β binding protein (LTBP) and is stored in the
extracellular matrix (ECM). The extracellular concentration of TGF-b activity is primarily
regulated by the conversion of latent TGF-b to active TGF-b. Plasmin, matrix metalloproteases 2
and 9, thrombospondin and avb6 integrin are known to activate TGF-b170.

1.3.2 TGF-b receptors
TGF-b receptors are transmembrane serine/threonine kinases. There are 7 type I receptors
and 5 type II receptors in the TGF-β superfamily in humans. In the absence of ligand, both type I
and type II receptors are present as homodimers. Upon ligand binding, type II TGF-b receptors
recruit type I TGF-b receptors to form a hetero-tetrameric complex of two TGF-b receptor type I
and two TGF-b receptor type II to induce signaling. TGF-b ligands can bind to two type I receptors,
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namely activin receptor like kinase 1 and 5 (ALK1 and 5) and only one type II TGF-b receptor
(TGFbR2)173. BMPs and GDFs are known to bind ALK2, 3 and 6, Activins can bind ALK4, while
Nodal binds to ALK7. After ligand binding, type II receptors phosphorylate type I receptors and
promote the binding and phosphorylation of downstream proteins in two independent signaling
routes, the SMAD-dependent canonical pathway and the SMAD-independent non-canonical
pathways174 (Fig. 1.3).

1.3.3 Canonical TGF-b signaling
SMADs can be classified into three groups: receptor-mediated SMADs (R-SMADs),
common-partner SMAD (Co-SMADs) and inhibitory SMADs (I-SMADs). There are eight SMAD
family members in humans. SMAD2 and 3 are substrates of TGF-b, nodal and activin receptors,
and SMAD1, 5, and 8 are substrates of the receptors for TGF-b, BMPs, GDFs and AMH. Only
one Co-SMAD, SMAD4, has been identified in mammals, which is used by all TGF-b superfamily
members. The class of the I-SMADs includes SMAD6 and 7. SMAD6 is an inhibitor of BMP
signaling, while SMAD7 inhibits both TGF-b/activin and BMP signaling175. In the SMADdependent pathways, activation of TGF-β receptor type I leads to phosphorylation of R-SMAD
proteins. After being phosphorylated by the receptor, R-SMADs together with the common
mediator SMAD4 translocate to the nucleus and interact with other transcription factors to regulate
transcription of target genes176. SMAD7 has been shown to form stable complex with TGF-b type
I receptors and therefore inhibit the phosphorylation of R-SMADs and the formation of
heterocomplex between R-SAMDs and SMAD4177. It has also been shown to compete with
SMAD4 to oligomerize with R-SMADs and directly inhibit R-SMAD activity178.
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1.3.4 Non-canonical TGF-b signaling
In addition to SMAD signaling, TGF-b can activate all three MAPK pathways, including
extra-cellular regulated kinase (ERK), c-Jun amino terminal kinase (JNK), and p38 mitogenactivated protein kinase (p38 MAPK)179. TGF-b also activates TGF-β-activated kinase 1 (TAK1;
also known as MAP3K7) and tumor necrosis factor (TNF) receptor-associated factor 4 and 6
(TRAF4 and TRAF6), which can led to JNK, nuclear factor-κB (NF-κB) and p38 MAPK
activation180,181. In addition, RHO, phosphoinositide 3-kinase (PI3K), AKT (also known as protein
kinase B) have all been shown to be activated by TGF-b182.

Figure 1.3. The TGF-b signaling pathways. Different ligands in the TGF-b superfamily binds
different combinations of TGF-b receptors I and II. TGF-bs can bind ALK1/TGFbR2 or ALK5/TGFbR2
and trigger SMAD1/5/8 or SMAD2/3 mediated SMAD-dependent canonical signaling or SMADindependent non-canonical kinase signaling. Figure adapted from Neuzillet et al183.
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1.3.5 TGF-b signaling in HSCs
TGF-β is known to inhibit the growth of many cell types, including epithelial, endothelial
and hematopoietic cells184,185. Specifically, in the hematopoietic system, multiple studies have
shown that TGF-β is a potent inhibitor of HSC growth in vitro186-188. Neutralizing TGF-β in vitro
releases HSC from quiescence189,190. Studies have suggested that TGF-β inhibits cell proliferation
by altering cytokine receptor expression, such as interleukin (IL)-1191 , IL-3, granulocyte
monocyte-colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF)192
and c-KIT (stem cell factor receptor)193, and by upregulating cyclin-dependent kinase inhibitors,
including p27194, p21195, p15196 and p57197. More recently, TGF-β has been shown to promote HSC
hibernation by inhibiting cytokine-mediated lipid raft clustering171. Interestingly, multiple studies
using genetic mouse models have provided conflicting results regarding the role of TGF-b in
regulating HSC function in vivo. Conditional deletion of Tgfbr1 did not have any effect on the
repopulating potential, self-renewal ability, or cell cycle of HSCs198. However, another group
reported that conditional deletion of Tgfbr2 resulted in a reduced HSC repopulating activity99.
Likewise, conditional deletion of Smad4, which mediates all canonical TGF-b signaling, resulted
in reduced HSC repopulating activity but did not alter quiescence199. The same group also reported
that overexpression of the inhibitory Smad, Smad7, led to a Smad4-dependent increase of selfrenewal ability200. On the other hand, Challen et al. showed that TGF-β signaling, while inhibiting
lymphoid-biased HSCs, could promote the proliferation of myeloid-biased HSCs201. One recent
study showed that HSCs exposed to TGF-b1 in vitro before transplantation had reduced short-term
and long-term reconstitution ability, and myeloid and T cell repopulating potential202. Using single
cell HSC culture, they found that TGF-b1 inhibited cell division while not affecting the quiescence.
Interestingly, using single cell RT-PCR, they showed that TGF-b1 did not affect cell cycle gene
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expression in single-cell cultured HSCs. Altogether, these conflicting studies suggest that the
effect of TGF-β on HSCs is likely complex and may depend on specific HSC subtypes.

1.3.6 TGF-b signaling in the bone marrow niche
The regulation of HSCs by TGF-β may come from the bone marrow microenvironment.
Megakaryocytes, which are in close proximity to HSCs100, are thought to be one of the major
sources of TGF-β in the bone marrow. Zhao et al. showed that HSCs located near megakaryocytes
had increased Smad2/3 activation101. Ablation of megakaryocytes led to a strong reduction of
TGF-b protein in the bone marrow, reduced phosphorylation of Samd2/3 in HSCs and induced
proliferation of HSCs101. Moreover, conditional deletion of Tgfb1 in megakaryocytes led to an
increase in HSPC number and loss of quiescence in HSCs. Non-myelinating Schwann cells, which
also are in close contact with HSCs, are thought to be another source of TGF-β in the bone
marrow99. Yamazaki et al. showed that these cells regulate the activation of TGF-β by integrinavb8, which binds to LAP and expose latent TGF-b to proteolytic cleavage by
metalloproteinases99. Moreover, denervation resulted in loss of HSCs and increased cell cycling99.

1.3.7 Interaction between TGF-b signaling and JAK-STAT signaling
Altered JAK-STAT signaling is the main cause of MPNs. Since TGF-b production is
elevated in MPN patients, how JAK-STAT signaling and TGF-b signaling interact and regulate
each other could be important to understand the disease pathogenesis. Evidence has suggested that
TGF-b signaling interacts with JAK-STAT signaling through multiple pathways. Activation of
JAK-STAT signaling has been shown to cause increased TGF-b production203,204 or induced TGF25

b signaling205,206 in multiple different cell types. On the other hand, studies have reported that
JAK-STAT signaling negatively regulates TGF-b signaling. Activated JAK-STAT signaling has
been shown to inhibit TGF-b signaling through activation of SMAD7207-209, an inhibitory SMAD
protein that blocks the activation of R-SMADs. Activated STAT3 has also been shown to inhibit
TGF-b signaling through direct interaction with SMAD3, which prevents the formation of
SMAD3-SMAD4 complex210. In addition, STAT3 could also negatively regulate SAMD3
expression through binding and recruiting of other proteins211,212. Conversely, there is evidence
that TGF-b signaling inhibits JAKs and STATs transcription213,214 and/or activation215. Finally,
studies provide evidence that TGF-b signaling and JAK-STAT signaling may act in a collaborative
manner to control gene expression involved in T cell differentiation216,217. Although these studies
have established that TGF-b and JAK-STAT signaling pathways interact, the impact of these
interactions on MPN disease pathogenesis is unknown.

1.4 JAK2 and Clonal Hematopoiesis
1.4.1 Clonal hematopoiesis
Clonal hematopoiesis is defined by overrepresentation of blood cells from an individual
clone of HSC (reviewed in218-220). Such event happens when a single HSC acquires specific
mutation that confers a fitness advantage. This phenomenon was originally discovered in the 1990s
when non-random X-chromosome inactivation (XCI) was found in the blood cells of female
patients with leukemia221 and also healthy females221,222. During female embryonic development,
one of the X-chromosome is randomly inactivated. Therefore, non-random XCI is an evidence of
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a clonal process. With the advances in genome sequencing in the early 2010s, three different
groups reported independently in 2014 the identification of mutations associated with
hematopoietic malignancies in the blood cells of individuals with no diagnosis of hematopoietic
cancers39-41. These three studies together have analyzed exome sequencing data from more than
32,000 individuals unselected for hematopoietic cancers and identified mutations in a very
restricted set of genes that led to clonal expansion in the blood. Mutations in epigenetic modifiers
(DNMT3A, TET2 and ASXL1) were the most common. DNA repair response genes (TP53 and
PPM1D) and splicing factors (SF3B1, SRSF2 and U2AF1) were also common. JAK2 was the only
tyrosine kinase found in these sets of genes. These studies also found that clonal hematopoiesis is
an age-related process and people with clonal hematopoiesis has around ten-fold increased risk of
developing hematopoietic malignancies. This phenomenon was later defined as clonal
hematopoiesis of indetermined potential (CHIP) or age-related clonal hematopoiesis (ARCH).

1.4.2 Clonal hematopoiesis and non-malignant diseases
Clonal hematopoiesis is not only associated with increased risk of hematopoietic cancers,
it is also linked to other non-malignant diseases. Multiple studies have found that clonal
hematopoiesis is associated with increased risk of mortality39,40,223. It is further identified that
individual with CHIP have a higher cardiovascular mortality and increased risk of ischemic stroke,
coronary heart disease, and myocardial infarction40,224. Importantly, the risk of developing
coronary heart disease was 12-fold higher in individuals with CHIP due to JAK2 mutations, which
is the highest and most significant among all CHIP mutations. Another study reported a 12-fold
higher risk of developing venous thrombosis in persons with JAK2-mutant associated CHIP
compared to those without CHIP225. Using a Jak2V617F mouse model, they have found that Jak2
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mutation resulted in increased neutrophil extracellular traps formation, which could increase the
risk of thrombosis. In addition, it has been shown in a high-fat diet induced atherosclerosis mouse
model that Jak2V617F enhances atherosclerosis, possibly due to increase inflammatory cytokine
production by microphages226. Therefore, although CHIP is not a malignancy, it is clear that there
is still clinical benefit to identify and treat individuals with CHIP to prevent progression to
malignancies or developing cardiovascular events. How to prevent further clonal expansion
requires more understanding on the mechanisms on how the mutations contributes to clonal
expansion.

1.4.3 Mechanisms for clonal hematopoiesis
Understanding the mechanism of how each mutation contributes to clonal expansion has
been one of the most active fields in hematology research since 2014; however, the majority of the
mechanisms are still not well known. The most clear mechanism being identified was that
mutations in DNA damage response genes, including TP53227 and PPM1D228,229, promote clonal
expansion despite the presence of DNA damage from genotoxic stress. How other mutations
promote clonal expansion is less clear.
Jak2V617F can drive clonal expansion in multiple mouse models. Mullally et al. showed that
Jak2V617F had subtle clonal advantage at 16 weeks but can achieved clonal dominance gradually
over time (>1 year) in a 1(Jak2V617F):3 (wild type) competitive repopulating assay of sorted LSK
(Lineage- Sca-1+ c-Kit+) cells20,21. Using Vav-Cre to induce the Jak2V617F knock-in in the model
Marty et al. generated, Hasan and colleagues found a stronger competitive advantage of Jak2V617F
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. Jak2V617F could expand and achieve clonal advantage at a 1(Jak2V617F):9 (wild type) total bone

marrow competitive transplantation assay. Using the Mx1-Cre driven Jak2V617F transgenic model
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generated by Teidt et al.42, Lundberg and colleagues showed an even stronger clonal advantage of
Jak2V617F cells that single HSC carrying Jak2V617F was able to expand and initiate MPN231. Since
JAK2 acts downstream of growth factor receptors, activating JAK2 mutations is suggested to
promote clonal expansion through enhancing proliferation of cells232. However, JAK2 was the only
tyrosine kinase found in CHIP. In addition to JAK2, tyrosine kinase mutations including BCR-ABL,
FMS-like tyrosine kinase 3 (FLT3), stem cell factor receptor (SCFR, or KIT), granulocyte colonystimulating factor receptor (CSF3R) and RAS are all frequently found in hematopoietic
malignancies233,234. These mutations usually, similar to JAK2, lead to constitutive activation of
signaling associated with proliferation and survival. Though, these mutations are typically
secondary events rather than the founding driver mutations235. Therefore, JAK2 mutations is likely
to have different mechanisms driving clonal expansion other than simply just promoting cell
proliferation. Recent studies have provided evidence that inflammatory stress could promote
TET2236 and DNMT3A237 mutated clonal hematopoiesis. Since JAK2 mutated megakaryocytes
produce elevated inflammatory cytokines including TGF-b, it is possible that JAK2 mutated cells
gain clonal advantage through the elevated inflammation signaling. Understand how elevated
inflammatory signaling contributes to JAK2 mutation clonal hematopoiesis can be beneficial in
preventing development of MPNs from CHIP.
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Chapter 2: TGF-b Signaling in Mesenchymal Stromal
Cells Contributes to Myelofibrosis Through Noncanonical JNK Signaling
2.1 Introduction
Myeloproliferative neoplasms (MPNs) are chronic myeloid malignancies characterized by
overproduction of myeloid lineage cells and myelofibrosis1. The development of myelofibrosis is
the most aggressive form of the disease with significant shortened survival238,239. Mutations occur
in the hematopoietic stem and progenitor cells (HSPCs) altering the JAK-STAT signaling
pathway, including JAK2V617F, MPL and Calreticulin mutations, are the major causes of these
diseases2. However, JAK1/2 inhibitor ruxolitnib only provides symptomatic relief but does not
reduce mutant allele burden, improve fibrosis, or prolong survival50. The only curative therapy for
MPN is allogeneic stem cell transplantation. Therefore, a better understanding of the mechanisms
of disease progression, especially the development of myelofibrosis, is needed to develop better
treatments.
Elevated inflammatory cytokines including TGF-b produced by megakaryocytes and
monocytes is found in MPN patients115-117. Prior studies provided evidence that increased TGF-b
may contribute to the development of myelofibrosis. Using a thrombopoietin (TPO)
overexpression model of MPN, Chagraoui et al. showed that deletion of Tgfb1 reduced but did not
completely abrogate the development of myelofibrosis119. Likewise, treatment with inhibitors
targeting TGFbR1 (Alk5) reduced myelofibrosis in Gatalow120 or MPLW515L122 mouse models of
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MPNs. These data have led to a clinical trial using a novel TGF-b1 & TGF-b3 inhibitor AVID200
in patients with myelofibrosis (NCT03895112). However, the role of TGF-b in the development
of myelofibrosis remains controversial. In all of the aforementioned studies, although reduced,
significant myelofibrosis remained despite inhibiting TGF-b signaling, raising the possibility that
there are other mediators of myelofibrosis. Consistent with this possibility, Decker et al. showed
that platelet-derived growth factor alpha signaling in Lepr+ mesenchymal stromal cells is required
for the development of myelofibrosis123. Moreover, Schneider et al. reported that Cxcl4 signaling
in Gli1+ mesenchymal stromal cells contributed to myelofibrosis124,125. The cell of origin
responsible for myelofibrosis also is controversial. As noted above, prior studies have implicated
Lepr+ or Gli1+ mesenchymal stromal cells as the target of inflammatory signaling leading to
myelofibrosis123,124,125. On the other hand, there are studies suggesting that monocyte-derived
fibrocytes158,159 or endothelial167 cells are the cell of origin.
In addition to myelofibrosis, changes in bone metabolism have also been identified in MPN
patients. Diffused osteosclerosis is one of the typical histology findings in severe cases of
myelofibrosis134-136. There is also evidence suggesting increased risk of osteoporotic fractures in
MPN patients when comparing to the general population126,128. Mechanisms for the altered bone
metabolism in MPN are not well-understood. One study suggested that increased osteoprotegerin
(OPG) secretion by endothelial cells, through inhibiting osteoclast function, contributed to the
development of osteosclerosis143. On the other hand, a prior study suggested that Jak2V617F
monocytes have an increased ability to form osteoclasts compared to healthy donors130.
We previously showed that TGF-b is essential for lineage specification of mesenchymal
lineage cells during development240. Losing TGF-b signaling in mesenchymal stromal cells during
embryonic development led to elevated adipogenesis and loss of osteoblasts. Interestingly, we
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identified that TGF-b promotes osteoblast formation through Smad4-dependent canonical
signaling, while it inhibits adipogenesis through non-canonical Mapk pathways. Although we
demonstrated that TGF-b signaling is dispensable for adult hematopoiesis niche, its role in
malignant hematopoietic niche is not well known. In this study, we tested the hypothesis that TGFb signaling in mesenchymal stromal cells is required for the development of myelofibrosis. We
further investigated the mechanisms on how TGF-b contributes to myelofibrosis. We identified
that TGF-b contributes to the formation of myelofibrosis through activating the Smad-independent
non-canonical JNK signaling in mesenchymal stromal cells. Our data provide evidence that
targeting JNK signaling may be beneficial to treating myelofibrosis in MPN patients.

2.2 Material and Methods
2.2.1 Mouse strains
Tgfbr2f/f (B6;129-Tgfbr2tm1Karl/J)241 mice, doxycycline-regulated Osx-Cre (B6.Cg-Tg Sp7tTA,tetO-EGFP/cre

1Amc/J)242 mice, Ai9 (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J)243 mice, UBC-

CreERT2 (B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/1J)244, Jak2V617F (B6N.129S6(SJL)-Jak2tm1.2Ble/AmlyJ)20,
Dmp1-Cre (B6N.FVB-Tg(Dmp1-cre)1Jqfe/BwdJ)245 mice were obtained from The Jackson
Laboratory. Tgfbr2f/- mice were generated by breeding Tgfbr2f/f with E2A-Cre (B6.FVB-Tg(EIIacre)C5379Lmgd/J)246 mice. Samd4f/f mice were a gift from Dr. Fanxin Long. All mice were backcrossed onto a C57Bl/6 background and were maintained under standard pathogen-free conditions
according to methods approved by the Washington University Animal Studies Committee. All
mice used in this study were 6-12 weeks old. Both male and female mice were used equally in
these studies. To induce recombination postnatally, Osx-Cre; Tgfbrf/- or Osx-Cre; Smad4f/f
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breeders were maintained on 200 ppm doxycycline chow, which was removed after pups were
born.

2.2.2 Bone marrow transplantation
6 to 12 weeks old Tgfbr2f/f, Tgfbr2f/-or Osx-Cre; Tgfbr2f/- recipient mice were lethally
irradiated with two 600 cGy doses, 16 hours apart. All irradiated recipient mice were placed on
prophylactic antibiotics (trimethoprim-sulfamethoxazole) for two weeks following the first dose
of irradiation.
To induce MPN in mice using MPLW515L retrovirus, c-kit+ HSPC from wild type mice were
enriched by CD117 (c-Kit) autoMACS beads (Miltenyi) and recovered in stem cell media (MEMalpha with 10% FBS, 100U Penicillin and Streptomycin, 10 ng/ml m-TPO, 10 ng/ml m-IL-3, 10
ng/ml m-FLT3L and 100 ng/ml m-SCF) overnight. To generate retrovirus carrying MPLW515L or
empty vector control, retrovirus packaging vector pCL-Eco were co-transfected with MSCVMPLW515L-iRES-GFP or empty vector to 293T cells. Freshly generated retrovirus was added to
HSPCs cultures along with polybrene (6 µg/ml). Cells were spin-infected under 2400 rpm in 30
°C for 90 mins and recovered in 5% CO2 37 °C incubator overnight. Half a million transduced cKit+ cells were injected retro-orbitally into recipients (wild type littermate controls, Osx-Cre;
Tgfbr2f/-, Dmp1-Cre; Tgfbr2f/f, Osx-Cre; Smad4f/f). Mice were sacrificed for analysis when at least
one of the mice in the same transplanted cohort started to look moribund (hunched, slow, thin).
To induce MPN in mice with Jak2V617F, donor bone marrow cells were collected from
UBC-CreERT2; Jak2V617F or Cre alone mice and two million total bone marrow cells were injected
retro-orbitally into lethally irradiated recipients. Six weeks after transplantation, mice were treated
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with 3 mg tamoxifen in corn oil through oral gavage for 5 doses (one dose per day) to induce Cre
expression. Mice were sacrificed for analysis five months after tamoxifen induction.

2.2.2 Immunofluorescence staining of mouse femur sections
Mouse femurs were fixed in 10% formalin for 24-48 hours at 4 °C. Bones were then
decalcified in 14% EDTA, pH 7.4, for 10-14 days at 4 °C. Following incubation in 30% sucrose
for 24 hours at 4 °C to dehydrate, bones were embedded in Optimal Cutting Temperature
Compound (Sakura Finetek). These tissue blocks were cut into 12 μm sections using a Leica CryoJane system (Leica Biosystems). For immunostaining, the slides were blocked with 5% donkey
serum in TBST buffer for one hour at room temperature. Slides were then incubated with primary
antibody overnight at 4 °C and were incubated with secondary antibody for one hour at room
temperature. The following antibodies were used: rabbit anti-Collagen I (Abcam, ab34710), rabbit
anti-Collagen III (Abcam, ab7778) and Alexa Fluor 647-conjugated donkey anti-rabbit IgG (H+L)
(Thermo Fisher). Finally, slides were mounted with ProLong Gold antifade reagent with DAPI
(Life Technologies). Images were acquired with an LSM 700 microscope (Carl Zeiss). Fluorescent
intensity was quantified using ImageJ.

2.2.3 Histology of mouse femur sections
Mouse femurs were fixed in 10% formalin for 24 hours at 4 °C. Bones were then
decalcified in 14% EDTA, pH 7.4, for 10-14 days at 4 °C and dehydrated via incubation in 30%,
50% and 70% ethanol for 15 mins each. Processed bones were further embedded in paraffin and
sectioned into 5 µm sections and stained for reticulin fibers or TRAP (Tartrate-resistant acid
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phosphatase) by the Musculoskeletal Research Histology Core in Washington University. Degree
of fibrosis were graded blindly by hematopathologists using adjusted criteria from the WHO
guideline.

2.2.4 Quantitative real-time PCR
To collect total bone marrow RNA, tibias from mice were either crushed (MPLW515L mice)
with mortor and pestle in 1 mL of Trizol or flushed (Jak2V718F mice) with 1 mL of Trizol
(Invitrogen). RNA was extracted following the manufacturer’s instructions. cDNA was prepared
using iScript reverse transcription supermix (Bio-Rad). Quantitative real-time PCR (qRT-PCR)
was performed using the TaqMan Universal RT Master Mix (Applied Biosystems) with no RT
controls. Data was collected on a OneStep Real-Time PCR System (Applied Biosystems). Taqman
probe primers were all from Thermo Fisher: Actb VIC-MGB (Mm04394036_g1), Tgfb1 FAMMGB (Mm01178820_m1), Tgfbr2 FAM-MGB (Mm03024091_m1), Col1a1 FAM-MGB
(Mm00801666_g1),

Col3a1

FAM-MGB

(Mm01254476_m1),

Acta2

FAM-MGB

(Mm01546133_m1) and Loxl1 FAM-MGB (Mm01145738).

2.2.5 Micro computed tomography (micro-CT) analysis
Mouse femurs were fixed in 10% formalin for 24 hours at 4 °C and then dehydrated in 70%
ethanol. Micro-CT scan and analysis were performed by Musculoskeletal Research Histology Core
in Washington University.
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2.2.6 Mesenchymal stromal cell culture
Total bone marrow from 3-4 weeks old wild type or Osx-Cre; Smad4f/f mice were collected
and plated on cell culture plates in MSC media (DMEM, 20% FBS, 100U Penicillin and
Streptomycin). Non-attached cells were removed the next day by gentally aspirating the media and
fresh media were added. Cells were washed with PBS and fresh media were added everyday for
another two days. Attached MSCs were expanded for three more days until around 80% confluncy
before plating for experiments. MSCs attached to cell culture plates strongly, so after
trypsinization, cells were scraped to insure efficient collection. For TGF-b1 stimulation
experiments, 200,000 MSCs were plated per well in 6-well plates and 10 ng/ml of TGF-b1 or
vehicle control (1% BSA in PBS) were added every 24-hour for total three doses. For MAP kinase
inhibitors treatments, 20 µM of MEK inhibitor (PD99050), p38 inhibitor (SB202190), JNK
inhibitor (SP600125), 1 µM of NFkB inhibitor (pevonedistat) or vehicle control (DMSO) were
added every 24-hour for total 3 doses. 24 hours after the last doses, cells were lysed by Trizol and
RNA was extratcted for qntification real-time RT-PCR analysis.

2.2.7 JNK inhibitor treatment in mice
MPLW515L retrovirus transduced HSPCs were transplanted into lethally irradiated wild type
recipients. One week after transplantation, mice were treated with vehicle control (0.5%
carboxymethyl cellulose, 0.25% Tween-80) or 50 mg/kg CC-930 twice daily through oral gavage
for three weeks. At the end of treatment, mice were sacrificed for analysis of MPN disease
phenotypes.
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2.2.8 Statistical analysis
Unpaired t-test was used to evaluate the significance of differences between two groups.
One-way ANOVA was used to evaluate the significance of differences between mutiple groups.
All data are presented as mean ± SEM.

2.3 Results
2.3.1 TGF-b signaling in mesenchymal stromal cells is required for the efficient
induction of myelofibrosis by MPLW515L in mice
To investigate the contribution of TGF-b signaling in mesenchymal stromal cells to the
pathogenesis of MPN, we used Osx-Cre; Tgfbr2f/f mice as transplant recipients for MPN mouse
models. Osterix, also known as Sp7, is a transcription factor expressed in mesenchymal lineage
cells, and Osx-Cre has been shown to target osteoblasts, osteocytes, adipocytes and perivascular
stromal cells247. Since there is only one type 2 receptor of TGF-b in mammals, deletion of Tgfbr2
can lead to complete abrogation of TGF-b signaling. Our group previously showed that
constitutive deletion of Tgfbr2 using Osx-Cre resulted in a runted phenotype, with mice dying
within 3 to 4 weeks of age240. Therefore, we utilized the tet-off system to delete Tgfbr2 postnatally
by removing doxycycline chow at birth. Recombination efficiency was analyzed using Osx-Cre;
Tgfbr2f/f; Ai9 mice, in which Osx-Cre targeted stromal cells express tdTomato. However,
incomplete deletion of Tgfbr2 was observed in sorted tdTomato+ stromal cells (Fig. 2.1A). In order
to solve this problem, we generated a null allele of Tgfbr2 by breeding E2a-Cre with Tgfbr2f/f mice.
E2a-Cre leads to recombination before implantation and, therefore, generates an inheritable null
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allele. These mice were bred with Osx-Cre; Tgfbr2f/f mice to generate Osx-Cre; Tgfbr2f/- mice and
Cre-recombinase activity was induced at birth by the removal of doxycycline. We again assessed
recombination efficiency by sorting tdTomato+ stromal cells from Osx-Cre; Tgfbr2f/-; Ai9 mice
after postnatal activation of Osx-Cre. In these cells, Tgfbr2 mRNA expression was reduced to
approximately 10% of wild type cells (Fig. 2.1A). Osx-Cre; Tgfbr2f/- mice had normal basal
hematopoiesis (data not shown), and they were used as transplant recipients for MPN disease
models.
We first studied the MPLW515L retroviral overexpression model of MPN. In brief, c-Kit
selected bone marrow hematopoietic stem/progenitor cells (HSPCs) were transduced with
retrovirus carrying empty vector (EV) or MPLW515L and transplanted into Tgfbr2f/f (TR2f/f), Tgfbr f/(TR2f/-) or Osx-Cre, Tgfbr2 f/- (Osx-TR2f/-) recipients (Fig. 2.1B). Consistent with MPN patients,
Tgfb1 mRNA expression is elevated in this mouse model of MPN (Fig. 2.1C). As reported
previously14, transplantation of MPLW515L transduced HSPCs resulted in a rapidly lethal MPN with
leukocytosis, erythrocytosis, thrombocytosis and splenomegaly (Fig. 2.1D-G). Similar results
were observed in Osx-TR2f/- recipients. Accordingly, mouse survival was similar between control
and Osx-TR2f/- recipients (Fig. 2.1H). These data suggest that TGF-b signaling in mesenchymal
stromal cells is dispensable for development of the MPN hematopoietic phenotypes.
We next investigated the myelofibrosis phenotype. As reported previously14, we observed
moderate to severe reticulin fibrosis in the bone marrow of both TR2f/f and TR2f/- recipients of
MPLW515L HSPCs (Fig. 2.2A-B). In contrast, reticulin fibrosis was significantly reduced in OsxTR2f/- recipients, with the majority of mice having no detectable fibrosis. To further quantify the
bone marrow fibrosis phenotype, we performed immunofluorescence staining for collagen I and
III and measured mRNA expression of fibrosis markers Collagen 3 (Col3a1) and a-smooth muscle
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actin (Acta2) in the bone marrow. In control recipients (data for TR2f/f and TR2f/- recipients were
combined), transplantation of MPLW515L HSPCs was associated with increased collagen I and III
deposition and increased mRNA expression of Col3a1 and Acta2 in the bone marrow, which were
mostly abrogated in Osx-TR2f/- recipients (Fig. 2.2C-E). Together, these data show that stromal
TGF-b signaling plays a key role in the development of myelofibrosis induced by MPLW515L.

2.3.2 TGF-b signaling in mesenchymal stromal cells is required for the efficient
induction of myelofibrosis by Jak2V617F in mice
Since Jak2V617F mutation is the most common mutation in MPN, we next tested whether
TGF-b signaling in mesenchymal stromal cells is required for Jak2V617F induced myelofibrosis.
Here we used UBC-CreERT2; Jak2V617F/+ mice, in which treatment with tamoxifen induces Crerecombination and activation of the Jak2V617F allele20. Total bone marrow cells from UBC-CreERT2;
Jak2V617F/+ or UBC-Cre ERT2 alone mice were transplanted into lethally irradiated control (TR2f/f or
TR2f/-) or Osx-TR2f/- recipients. Six weeks after transplantation, mice were treated with tamoxifen
to induce Jak2V617F expression. Tgfb1 mRNA expression in total bone marrow was confirmed to
be elevated in this model (Fig. 2.3A). Consistent with a prior report20, control recipients of
Jak2V617F cells developed marked erythrocytosis and moderate leukocytosis, thrombocytosis and
splenomegaly (Fig. 2.3B-E). A similar hematopoietic phenotype was observed in Osx-TR2f/recipients. Mice were sacrificed approximately five months after tamoxifen treatment to assess
bone marrow fibrosis. Consistent with the prior report, the degree of myelofibrosis in this Jak2V617F
model was less than that observed in the MPLW515L model. Indeed, reticulin fibrosis in the bone
marrow was not detected. However, there was a modest but significant reduction of bone marrow
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cellularity found in control recipients of Jak2V617F cells while Osx-TR2f/- recipients recovered it
(Fig. 2.3F). Moreover, by immunostaining, a modest increase in collagen I and collagen III
deposition were observed in the bone marrow of control recipients transplanted with Jak2V617F
cells, which was significantly reduced in Osx-TR2f/- recipients (Fig. 2.3G-H). Collectively, these
data suggest that TGF-b signaling in mesenchymal stromal cells is required for the efficient
induction of myelofibrosis in both Jak2V617F and MPLW515L models of MPNs in mice but is
dispensable for the hematopoietic phenotypes.

2.3.3 TGF-b signaling in mesenchymal stromal cells is dispensable for the
induction of osteosclerosis by MPLW515L in mice
Difficulty in aspirating bone marrow in patients with myelofibrosis is common, and it has
been attributed to the presence of myelofibrosis and osteosclerosis248. Consistent with this finding,
we consistently were unable to flush bone marrow from control mice transplanted with MPLW515L.
However, despite the absence of detectable myelofibrosis, we also were unable to flush bone
marrow from Osx-TR2f/- recipients. Moreover, decreased bone marrow cellularity, a feature
attributed to myelofibrosis and osteosclerosis, was similar in control and Osx-TR2f/- mice
transplanted with MPLW515L (Fig. 2.4A). These observations suggest that osteosclerosis may be
responsible for the reduction in bone marrow cellularity in MPLW515L-induced MPN. Indeed,
increased trabecular bone was found in the epiphyseal and metaphyseal region of femurs from both
control and Osx-TR2f/- recipients (Fig. 2.4B). This phenotype is currently being analyzed by microCT scan, which will provide definitive quantification on the trabecular bone and cortical bone
volumes. Increased trabecular bone growth may be a result of decreased osteoclast number or
40

function. Using TRAP (Tartrate resistant acid phosphatase) staining for bone marrow sections, we
noticed that TRAP stained osteoclasts were increased in both control and Osx-TR2f/- recipients of
MPLW515L. We will measure CTX-I (c-terminal telopeptide) in the serum of these mice as an
indicator for osteoclast function. In addition to the osteosclerosis phenotype, reduction of niche
factors expression, including Cxcl12, Osteocalcin (Bglap) and Kit ligand (Kitl, also known as Stem
cell factor), is also observed in MPLW515L mice and losing Tgfbr2 in stromal cells did not recover
their expression levels (Fig. 2.4D). These data suggest that osteosclerosis and changes in niche
factor expression in MPLW515L-induced MPN are independent of TGF-b signaling in mesenchymal
stromal cells.

2.3.4 TGF-b signaling in osteolineage cells is not required for the development
of MPLW515L induced myelofibrosis in mice
Osx-Cre targets a wide range of bone marrow stromal populations, including osteolineage
cells, perivascular CAR cells and adipocytes247. To further refine the target population on which
TGF-b acts to induce myelofibrosis, we utilized Dmp1-Cre; Tgfbr2f/f (Dmp1-TR2f/f) mice as
transplantation recipients of MPLW515L transduced HSPCs. Prior lineage tracing studies by our
group showed that the Dmp1-Cre transgene targets all osteoblasts, osteocytes, and a subset of
CXCL12 abundant reticular (CAR) cells that likely represent osteolineage precursors249. We first
generated Dmp1-Cre; TR2f/f; Ai9 mice to assess targeting efficiency. Indeed, in tdTomato+ stromal
cells sorted from these mice, Tgfbr2 mRNA was nearly undetectable (Fig. 2.5A). A similar
myeloproliferative hematopoietic phenotype and decrease of bone marrow cellularity were
observed in control and Dmp1-TR2f/f recipient mice transplanted with MPLW515L transduced HSPCs
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(Fig. 2.5B-F). Interestingly, the myelofibrosis also was similar. Specifically, a similar degree of
reticulin fibrosis and increase in Col3a1 mRNA expression were observed in control and Dmp1TR2f/f recipients (Fig. 2.5G-I). These data suggest that TGF-b signaling in osteoblast-lineage cells
is dispensable for the development myelofibrosis in mice.

2.3.5 Canonical TGF-b signaling in mesenchymal stromal cells is not required
for the development of MPLW515L induced myelofibrosis in mice
To investigate the contribution of canonical TGF-b signaling to the development of
myelofibrosis, we transplanted MPLW515L transduced HSPCs into Osx-Cre; Smad4flfl (OsxSmad4f/f) mice. SMAD4 is required for all canonical TGF-b signaling174. We previously showed
that post-natal activation of Osx-Cre by removing doxycycline chow at birth efficiently deletes
Smad4 in mesenchymal stromal cells in the bone marrow250. Moreover, we previously showed that
basal hematopoiesis is normal in Osx-Smad4f/f mice250. The myeloproliferative hematopoietic
phenotypes and decreased bone marrow cellularity were similar in control and Osx-Smad4f/f
recipients transplanted with MPLW515L transduced HSPCs (Fig. 2.6A-E). Moreover, myelofibrosis,
as measured by Col3a1 mRNA expression, reticulin fibrosis, and collagen I and III deposition,
was similar in control and Osx-Smad4f/f recipients (Fig. 2.6F-J). These data show that Smad4dependent TGF-b signaling in not required for the generation of myelofibrosis by MPLW515L in
mice.
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2.3.6 JNK activation by TGF-b contributes to the development of MPLW515L
induced myelofibrosis in mice
To characterize TGF-b signaling pathways contributing to the induction of a fibrogenic
program in mesenchymal stromal cells, we cultured primary mesenchymal stromal cells from wild
type and Osx-Smad4f/f mice. Treatment of wild type cultures with TGF-b1 induced mRNA
expression of fibrosis-related genes Col1a1, Acta2, and Loxl1 (Lysyl oxidase like 1) (Fig. 2.7B-D).
Although basal expression of Col1a1 and Acta2 mRNA is modestly reduced in Smad4-deficient
mesenchymal stromal cells, TGF-b1-induced increases in these genes were similar to wild type
cells. These data are consistent with the in vivo studies of Osx-Smad4f/f mice and suggesting that
non-canonical TGF-b signaling in mesenchymal stromal cells mediates the myelofibrosis
phenotype.
Non-canonical TGF-b signaling includes the activation of ERK, JNK, p38, PI3-kinase, and
NFkB pathways (Fig. 2.7A)179. To identify the non-canonical pathways contributing to TGF-b1
induced fibrosis-related gene expression, we treated wild type mesenchymal stromal cells with
TGF-b1 and the indicated small molecule inhibitors and quantified mRNA expression of Col1a1,
Acta2, and Loxl1 (Fig. 2.7E-J and Fig. 2.8A-F). Treatment with PD99059 (a MEK inhibitor)
resulted in a modest change in the basal expression of these genes, but it did not block their
induction by TGF-b1 (Fig. 2.7E and Fig. 2.8A-B). Treatment with SB202190 (a p38 inhibitor) or
pevonedistat (a NFkB inhibitor) was associated with a significant decrease in basal Col1a1 and
Acta2 mRNA expression, but also did not prevent TGF-b1-induced increases in these genes (Fig.
2.7F-G and Fig. 2.8C-F). In contrast, treatment with SP600125, a pan-JNK inhibitor, significantly
reduced TGF-b1-induced increases in Col1a1, Acta2, and Loxl1 mRNA expression (Fig. 2.7H-J).
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These data suggest TGF-b1-induced activation of JNK is a key step in the induction of a fibrogenic
program in murine mesenchymal stromal cells, at least in vitro.
Finally, to assess the impact of JNK activation of the development of myelofibrosis, we
treated wild type mice transplanted with MPLW515L-transduced HSPCs with CC-930 (Tanzisertib),
a pan-JNK inhibitor, twice daily for three weeks beginning seven days after transplantation. While
treatment with CC-930 had no effects on hematopoietic phenotypes of MPLW515L induced MPN
(Fig. 2.9 A-D), we observed a modest but significant recover of bone marrow cellularity (Fig.
2.9E), market reduction of reticulin fibrosis (Fig. 2.9F-G) and reduced Col3a1 RNA expression in
the bone marrow (Fig. 2.9H). This data provide evidence that targeting JNK signaling can be
beneficial in treating myelofibrosis.

2.4 Discussion
The cause of myelofibrosis and the cell of origin is controversial. Although prior studies
have suggested that TGF-b is a key contributor of myelofibrosis, each of these studies had
limitations. The studies using TPO overexpression119 or GATA1low120 models do not represent
mutations found in patients with MPN; thus, their clinical relevance is uncertain. Studies using
TGFbR1 (ALK5) inhibitors120,122 only targets part of the TGF-b signaling because TGF-b can bind
to ALK1/TGFbR2 hetero-tetramers as well. Indeed, Alk1 and Alk5 are expressed at similar level
in bone marrow stromal cells251. This could be the reason that they did not observe complete
abrogation of bone marrow fibrosis. Our data offer a comprehensive analysis of the contribution
of TGF-b signaling in mesenchymal lineage stromal compartments using genetic Tgfbr2 deletion
models combining with two MPN mouse models carrying the most common mutations in patients,
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MPLW515L and Jak2V617F. We showed that abrogating TGF-b signaling in Osx-Cre targeted
mesenchymal stromal cells significantly alleviated bone marrow fibrosis. While three of the nine
Osx-TR2f/- mice transplanted with MPLW515L developed modest fibrosis, this could be due to the
10% residual Tgfbr2 expression which resulted in incomplete deletion of TGF-b signaling.
Nevertheless, the overall fibrosis level quantified by multiple methods were significantly relieved
in Osx-TR2f/- recipients, providing strong evidence that TGF-b signaling in mesenchymal stromal
population is the key modulator of myelofibrosis.
Two previous studies have suggested that Lepr+123 or Gli1+124 mesenchymal stromal cells
are the key driver of myelofibrosis. Lineage tracing study has shown that Lepr+ cells largely
overlapped with Osterix+ cells, both target all mesenchymal lineage populations252. Gli1 was
originally identified as an incisor mesenchymal stem cell marker253 and further found to mark
perivascular mesenchymal stem cells and contributes to solid organ fibrosis254. However, no
detailed fate mapping has been done on Gli1+ cells in the bone marrow. Therefore, whether Gli1+
cells are also overlapping with Osterix+ and Lepr+ mesenchymal stromal populations is not known.
Nevertheless, our data is consistent with these two previous reports that mesenchymal stromal cell
is the major contributor to the formation of myelofibrosis.
Within the mesenchymal compartment, our data show that cells targeted by Dmp1-Cre are
not required for the TGF-b induced fibrosis. We have previously performed lineage tracing of the
Dmp1 targeted populations and identified that it targets all osteoblasts and 30% of CAR cells249.
This data suggest that it is not the osteolineage cells, but rather perivascular stromal cells, that are
the TGF-b-targeted cell population that is responsible for myelofibrosis. However, there is no
optimal genetic model that can specifically target this population in mice. Our data has therefore
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provided the best available evidence on dissecting the key population that is regulating
myelofibrosis phenotypes with limited genetic tools.
TGF-b signaling consists of the SMAD4-dependent canonical signaling and SMAD4independent non-canonical signaling. Using Osx-Cre; Smad4f/f mice as transplant recipients, we
further showed that it is not the SMAD4-dependent canonical signaling that is contributing to
TGF-b-induced fibrosis. Of note, canonical signaling by other TGF superfamily members, such as
bone morphogen proteins (BMPs) and activins, are also disrupted in these mice255. Indeed, these
other members of TGF family have never been suggested to be involved in myelofibrosis.
Moreover, we reported recently that postnatal deletion of Smad4 in Osterix targeted mesenchymal
stromal cells does not affect the maintenance of hematopoietic niche under both homeostatic and
stress conditions250. Using primary mouse MSC cultures, we identified that non-canonical JNK
pathway contributes to TGF-b induced fibrosis. Treatment with a pan-JNK inhibitor in MPLW515L
mice further suggests that targeting JNK signaling early in the disease progression can prevent the
formation of myelofibrosis. Our data is in line with a previous study showing that c-Jun, the
downstream target of JNK, is a fibrosis marker in multiple organs, including bone marrow256.
Indeed, this study showed that overexpression of c-Jun caused severe bone marrow fibrosis in
mice. In addition, a study using inhibitor of fibrocytes, pentraxin-2, demonstrated improvement in
myelofibrosis in the MPLW515L model of MPN158. Interestingly, this inhibitor has also been shown
to inhibit c-Jun and AP-1 signaling257, both are downstream targets of JNK. These evidence along
with our data support the importance of JNK signaling in the development of myelofibrosis. There
have been two JNK inhibitors in clinical trials for other fibrosis related diseases, PGL5001 for
inflammatory endometriosis (NCT01630252) and CC-930 in idiopathic pulmonary fibrosis
(NCT01203943). This provides potential clinical application for targeting JNK signaling in
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myelofibrosis patients. Though, it requires additional testing on whether inhibition of JNK
signaling can reverse myelofibrosis after the reticulin fibers are formed.
Although our data provide strong evidence that TGF-b signaling in mesenchymal stromal
cells is essential for the development of myelofibrosis, some existing reports have suggested
otherwise. One previous study using Lepr-Cre; Pdgfraf/f mice has shown that PDGF signaling in
Lepr+ stromal cells is the major contributor of TPO overexpression induced myelofibrosis123.
Hence, we also tested in our MSC culture model whether PDGF could induce fibrosis associated
gene expression. However, we did not observe any changes in Col3a1 and Acta2 expression in
MSCs treated with either PDGF-AA or PDGF-BB (Fig 2.10A-B). Unlike TGF-b receptors, the
two PDGF receptors, PDGFRa and PDGFRb, can form both homodimers and heterodimers to
transduce signals and they share most of the PDGF ligands258. Since both Pdgfra and Pdgfrb are
highly expressed on mesenchymal stromal compartments based on recent single cell RNA-seq
data251, it remains intriguing that only deleting Pdgfra could abrogate bone marrow fibrosis.
Nevertheless, PDGF signaling also activates the JNK signaling259. It is possible that TGF-b and
PDGF both contribute to the formation of fibrosis through this pathway.
The other group has reported that CXCL4 (also known as platelet factor 4, PF4) is the key
factor for myelofibrosis formation124,125. Deletion of Cxcl4 in the hematopoietic compartment
ameliorated bone marrow fibrosis in multiple mouse models of MPNs. However, the receptor for
CXCL4, CXCR3, is not expressed on the mesenchymal stromal cells251. Therefore, CXCL4 could
function only as an indirect factor in inducing fibrotic changes in the stromal population. Indeed,
TPO overexpression in Cxcl4-/- megakaryocytes no longer led to elevated TGF-b when comparing
the empty vector control125. This suggests that CXCL4 could act upstream of TGF-b in
contributing to the development of myelofibrosis.
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Changes in bone metabolism have not been a well characterized phenotype in MPN
disease. Whether they share the same stimulating factors with fibrosis phenotype remains
unknown. We have found in the MPLW515L model that the osteosclerosis phenotype is independent
of TGF-b signaling in mesenchymal stromal compartments. While a previous study has suggested
that deletion of Tgfb1 in hematopoietic compartments in TPO induced MPN prevented
osteosclerosis in mice119, this effect could be completely hematopoietic-dependent. Since
osteoclasts have a hematopoietic origin, it is highly likely that MPN associated mutations and the
elevated TGF-b production contribute to altered osteoclasts function. Detailed analysis on
osteoclasts and osteoblasts functions are required to further understand how mutations in
hematopoietic compartments or TGF-b may contribute to increased trabecular bone formation.
Alteration of the bone marrow niche by malignant hematopoietic clone has been found in
multiple hematopoietic malignancies102. Our results along with previous studies provide strong
evidence that the mutant MPN clones secrete inflammatory cytokines that can promote the
development of bone marrow fibrosis and alter the bone marrow niche. Currently, the available
therapies for MPNs only target the malignant hematopoietic compartments. Combinational
therapies targeting both the malignant clones and the altered niche may be beneficial to the
treatment of myelofibrosis. Our data suggests that JNK signaling may be a novel target of the
malignant niche of myelofibrosis.
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2.7 Figures
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Figure 2.1. TGF-b signaling in Osx-Cre targeted mesenchymal stromal cells is not required
for the development of the myeloproliferative phenotype by MPLW515L. (A) Tgfbr2 mRNA
expression relative to b-actin (Actb) mRNA in sorted lineage- tdTomato+ bone marrow stromal
cells. (B) Schematic of experimental design. (C) Tgfb1 mRNA expression relative to Actb in total
bone marrow; EV: empty vector. (D) White blood cell (WBC) count, (E) red blood cell (RBC)
count, (F) platelet (PLT) count, (G) spleen weight, (H) Kaplan Meier estimates of survival. Data
represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by Student’s t-test or
one-way ANOVA.
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Figure 2.2. TGF-β signaling in Osx-Cre targeted mesenchymal stromal cells is essential for
the development of myelofibrosis by MPLW515L. (A) Representative photomicrographs of femur
sections stained for reticulin (60X). (B) Average score of fibrosis grading in the diaphysis and
epiphysis. (C) Representative photomicrographs of femur sections stained for collagen I (yellow)
or collagen III (red); DAPI stains nuclei in blue; EV: empty vector. (D) Normalized fluorescence
intensity for collagen I and III. (E) mRNA expression levels of Collagen 3 (Col3a1) and α-smooth
muscle actin (Acta2) relative to Actb in total bone marrow. Data represent the mean ± SEM.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA.
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Figure 2.3. TGF-b signaling in Osx-Cre targeted mesenchymal stromal cells is essential for
the increased collagen deposition in Jak2V617F mouse model of MPN. (A) Tgf1b1 mRNA
expression relative to Actb in total bone marrow. (B) White blood cell (WBC) count, (C) red blood
cell (RBC) count, (D) platelet (PLT) count, (E) spleen weight and (F) bone marrow cellularity per
pelvis. (G) Representative photomicrographs of femur sections stained for collagen I (yellow) or
collagen III (red); DAPI stains nuclei in blue. (H) Normalized fluorescence intensity for collagen
I and III. Data represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by oneway ANOVA.
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Figure 2.4. MPLW515L induced osteosclerosis and decreased niche factor expression are
stromal TGF-b signaling independent. (A) Bone marrow cellularity per pelvis. (B)
Representative photomicrographs of femur sections showing trabecularization at epiphysis and
metaphysis (10X). (C) Representative photomicrographs of femur sections stained for TRAP
(40X). (D) mRNA expression levels of Cxcl12, Osteocalcin (Bglap) and Kit ligand (Kitl) relative
to Actb in total bone marrow. Data represent the mean ± SEM. ***p<0.001, ****p<0.0001 by oneway ANOVA.
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Figure 2.5. TGF-β signaling in Dmp1-Cre targeted osteolineage cells is not required for the
development of myelofibrosis by MPLW515L. (A) Tgfbr2 mRNA expression relative to Actb in
sorted lineage- tdTomato+ bone marrow stromal cells. (B) White blood cell (WBC) count, (C) red
blood cell (RBC) count, (D) platelet (PLT) count (E) spleen weight and (F) bone marrow cellularity
per pelvis; EV: empty vector. (G) Col3a1 mRNA expression relative to Actb in total bone marrow.
(H) Representative photomicrographs of femur sections stained for reticulin (60X). (I) Average
score of fibrosis grading in the diaphysis and epiphysis. Data represent the mean ± SEM. **p<0.01,
***p<0.001, ****p<0.0001 by one-way ANOVA.
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Figure 2.6. TGF-β does not contribute to the formation of myelofibrosis through its canonical
signaling. (A) White blood cell (WBC) count, (B) red blood cell (RBC) count, (C) platelet (PLT)
count, (D) spleen weight and (E) bone marrow cellularity per pelvis; EV: empty vector; Ctrl: mix
of Smad4f/f and TR2f/f. (F) Col3a1 mRNA expression relative to Actb in total bone marrow. (G)
Representative photomicrographs of femur sections stained for reticulin (60X). (H) Average score
of fibrosis grading in the diaphysis and epiphysis. (I) Representative photomicrographs of femur
sections stained for collagen I (yellow) or collagen III (red); DAPI stains nuclei in blue. (J)
Normalized fluorescence intensity for collagen I and III. Data represent the mean ± SEM. *p<0.05,
***p<0.001, ****p<0.0001 by one-way ANOVA.
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Figure 2.7. TGF-β contributes to the fibrosis gene expression through non-canonical JNK
signaling. (A) Canonical and non-canonical TGF-β signaling pathways. (B-D) Mesenchymal
stromal cell cultures were generated from wild type (WT) or Osx-Cre; Smad4fl/fl (Smad4KO) mice.
Cells were treated for 72 hours with 10 ng/ml of TGF-β1. Shown is the relative mRNA expression
of Col1a1 (B), Acta2 (C), and Loxl1 (D). (E-G) Relative Col1a1 mRNA in WT cultures treated
with TGF-β1 and one of the following inhibitors: the MEK inhibitor PD99059 (E), the p38
inhibitor SB202190 (F), or the NFκB inhibitor Pevonedistat (G). (H-I) Relative mRNA expression
in WT cultures treated with TGF-β1 and the JNK inhibitor SP600125 for the following genes:
Col1a1 (H), Acta2 (I), or Loxl1 (J). Data represent the mean ± SEM. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 by one-way ANOVA.
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Figure 2.8. Acta2 and Loxl1 mRNA expression in cultured MSC treated with kinase
inhibitors and TGF-β1. (A-B) Relative mRNA expression of Acta2 (A) and Loxl1 (B) in wild
type MSC cultures treated with TGF-β1 and the MEK inhibitor PD99059. (C-D) Relative mRNA
expression of Acta2 (C) and Loxl1 (D) in wild type MSC cultures treated with TGF-β1 and the p38
inhibitor SB202190. (E-F) Relative mRNA expression of Acta2 (E) and Loxl1 (F) in wild type
MSC cultures treated with TGF-β1 and the NFκB inhibitor Pevonedistat. Data represent the mean
± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA.
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Figure 2.9. JNK inhibitor alleviated fibrosis phenotypes in MPLW515L induced MPN. (A)
White blood cell (WBC) count, (B) red blood cell (RBC) count, (C) platelet (PLT) count, (D)
spleen weight and (E) bone marrow cellularity per pelvis (F) Representative photomicrographs of
femur sections stained for reticulin (60X). (G) Average score of fibrosis grading in the diaphysis
and epiphysis. (H) Col3a1 mRNA expression relative to Actb in total bone marrow. EV: empty
vector; VE: vehicle treated control. Data represent the mean ± SEM. *p<0.05, **p<0.01 by oneway ANOVA.

Figure 2.10. PDGF does not increase fibrosis markers expression in cultured MSCs. (A-B)
Relative mRNA expression of Col1a1 (A) and Acta2 (B) in wild type MSC cultures treated with
TGF-β1, PDGF-AA and PDGF-BB. Data represent the mean ± SEM. ****p<0.0001 by one-way
ANOVA.
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Chapter 3: TGF-b Signaling Contributes to the Clonal
Dominance of JAK2 Mutant Hematopoietic Stem Cells
3.1 Introduction
Myeloproliferative neoplasms (MPNs) are chronic myeloid malignancies arise from the
hematopoietic stem and progenitor cells (HSPCs). Mutations altering the JAK-STAT signaling
pathway is the major cause of BCR-ABL- MPNs2. JAK2V617F mutation is known to cause more than
half of all MPN cases. In addition, JAK2V617F has also been found in individuals with clonal
hematopoiesis39-41. Nevertheless, how JAK mutations contributes to clonal expansion is not well
characterized. Using knock-in mouse models, multiple studies have shown that Jak2V617F can drive
clonal expansion20,21,230,231. Since JAK2 is the downstream kinase of multiple growth factor
receptors, activating JAK2 mutations are assumed to promote clonal expansion through enhancing
proliferation of cells232. However, among all of the tyrosine kinases known to contribute to
myeloid malignancies, JAK2 is the only one found in clonal hematopoiesis. In addition to JAK2,
tyrosine kinase mutations including BCR-ABL, FMS-like tyrosine kinase 3 (FLT3), stem cell factor
receptor (SCFR, or KIT), granulocyte colony-stimulating factor receptor (CSF3R) and RAS are all
frequently found in hematopoietic malignancies233,234. These mutations usually, similar to JAK2,
result in constitutive activation of signaling associated with proliferation and survival. Therefore,
JAK2 mutations can potentially drive clonal expansion through mechanisms other than by
promoting cell proliferation.
Increased

inflammatory

cytokines,

including

TGF-b,

produced

by

malignant

megakaryocyte and monocytes in the bone marrow microenvironment are present in most cases of
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MPNs115-117. Recent studies have provided evidence that inflammatory stress could promote
TET2236 and DNMT3A237 mutated clonal hematopoiesis. Therefore, it is also possible that JAK2
mutated cells gain clonal advantage through the elevated inflammation signaling. Although we
and others have shown that TGF-b contributes to the development of bone marrow fibrosis in
MPN patients, its role in the hematopoietic phenotypes of the disease is not well understood.
Multiple prior studies have shown that TGF-b suppresses the proliferation of HSPCs in vitro186188

, while neutralizing TGF-β releases HSC from quiescence189,190. However, its impact on HSCs

in vivo is less clear. Studies using genetic mouse models have provided conflicting results
regarding the role of TGF-b in regulating HSC function in vivo. While conditional deletion of
Tgfbr1 did not have any effect on the repopulating potential, self-renewal ability and cell cycle of
HSCs198, conditional deletion of Tgfbr2 were found to reduce HSC repopulating activity99.
Conditional deletion of Smad4, which mediates all canonical TGF-b signaling, resulted in reduced
repopulating ability, while maintaining normal differentiation ability and intact cell cycle199.
Overexpression of the inhibitory Smad, Smad7, led to a Smad4 dependent increase of self-renewal
ability200. Challen et al. showed that TGF-β inhibited lymphoid-biased HSCs while promoting
proliferation of myeloid-biased HSCs201. Altogether, these conflicting studies suggest that the
effect of TGF-β on HSCs is more complex than originally thought and may depend on specific
HSC subtypes.
Here, we explore the hypothesis that HSPCs carrying a Jak2V617F mutation are resistant to
the suppressive effects of TGF-b, conferring a fitness advantage that contributes to their expansion
in MPNs.
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3.2 Material and Methods
3.2.1 Mouse strains
UBC-CreERT2

(B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/1J)244,

Mx1-Cre

(B6.Cg-Tg(Mx1-

cre)1Cgn/J)260 mice, Jak2V617F/+ (B6N.129S6(SJL)-Jak2tm1.2Ble/AmlyJ)20, Tgfbr2f/f (B6;129Tgfbr2tm1Karl/J)241, Ly5.1 (B6.SJL-Ptprca Pepcb/BoyJ) mice were obtained from The Jackson
Laboratory. All mice were in C57Bl/6 background and were maintained under standard pathogenfree conditions according to methods approved by the Washington University Animal Studies
Committee. All mice used in this study were 6-12 weeks old. Both male and female mice were
used equally in these studies.

3.2.2 Colony forming unit assay
20,000 total bone marrow cells or 125 sorted phenotypic HSCs (lineage- c-Kit+ Sca-1+
CD150+ cd48-) from wild type or Mx1-Cre; Jak2V617F mice that have been treated with five doses
of 300 ug polyinosinic–polycytidylic (pIpC, Millipore Sigma) through intraperitoneal injection
and recovered for at least four weeks were plated into methylcellulose (HSC007, R&D) with or
without 10 ng/ml TGF-b1. Colonies were counted one week after plating. 20,000 (for total bone
marrow) or 10,000 (for sorted HSCs) cells were re-plated into methylcellulose without TGF-b1.
Colonies were counted one week after plating and the re-plating procedures were repeated until no
colonies were formed.
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3.2.3 Competitive repopulating assay
For one to one competitive repopulating assays, bone marrow cells from wild type
(Ly5.1/5.2) and UBC-CreERT2; Tgfbr2f/f (Ly5.2) or UBC-CreERT2; Jak2V617F (Ly5.1/5.2) and UBCCreERT2; Jak2V617F; Tgfbr2f/f (Ly5.2) were mixed at one to one ratio and transplanted into lethally
irradiated (600 cGy twice, 16 hours apart) wild type (Ly5.1) recipients. For five to one competitive
repopulating assays, bone marrow cells from wild type (Ly5.1/5.2) or UBC-CreERT2; Tgfbr2f/f
(Ly5.1/5.2) and UBC-CreERT2; Jak2V617F (Ly5.2) or UBC-CreERT2; Jak2V617F; Tgfbr2f/f (Ly5.2)
were mixed at five to one ratio and transplanted into lethally irradiated (600 cGy twice, 16 hours
apart) wild type (Ly5.1) recipients. Six weeks post transplantation, mice were treated with 9 doses
(one dose per day) of 3 mg Tamoxifen in corn oil to induce Cre expression. Peripheral blood
lineage chimerism were checked every four weeks and mice were sacrificed at 12-14 weeks post
tamoxifen for bone marrow analysis.

3.2.4 Flow cytometry
Peripheral blood and bone marrow were processed for flow cytometry as previously
described261. Cells were analyzed on a Gallios flow cytometer (Beckman Coulter) or sorted on a
Sony SY3200 “Synergy” high-speed cell sorter (Sony). Data analysis was done using FlowJo
version 10.7.1 software (TreeStar). The following antibodies were used for staining murine cells:
Gr-1 (RB6-8C5), Ter119 (TER-119), CD117 (2B8), CD48 (HM48-1), CD45 (30-F11), CD45.1
(A20) and CD45.2 (104) are from eBiosciences; B220 (RA3-6B2), CD3e (145-2C11), CD115
(AFS98), Sca-1 (D7), CD150 (TC15-12F12.2) are from BioLegend. Ki67 (B56) and p-Smad2/3
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(O72-670) are from BD biosciences. FxCycle (Thermo Fisher Scientific) were used to detect DNA
content.
For flow cytometry of phosphorylated Smad2/3, freshly isolated bone marrow cells were
incubated with 10 ng/ml TGF-b1 (Peprotech) for 5, 15, 30 and 60 mins in MEMalpha plus 10%
FBS in 37 °C. Cells were then stained for cell surface markers before being fixed with Lyse/Fix
Buffer (BD bioscience) and permeabilized with Perm Buffer III (BD Bioscience) per
manufacturer’s instructions. Finally, cells were stained for phosphorylated Smad2/3.
For cell cycle analysis, cells were stained for cell surface markers before being fixed and
permeabilized with BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit per
manufacturer’s instructions. Cells were then blocked with 5% goat serum for 10 mins before being
stained for Ki-67 and FxCycle.
For EdU (5-ethynyl-2’-deoxyuridine) labeling experiment, mice were treated with 25
mg/kg of EdU (Thermo Fisher) through intraperitoneal injection 16 hours before analysis. Cells
were stained for cell surface markers before being fixed and labeled for EdU by Click-iT™ EdU
Cell Proliferation Kit (Thermo Fisher) based on manufacturer’s instruction.

3.2.5 RNA-sequencing
Wild type or Mx1-Cre; Jak2V617F (4 weeks post pIpC) mice were treated with 2 µg of TGFb1 or vehicle control (0.1% BSA in PBS) through intraperitoneal injection 24 and 12 hour before
being sacrificed. Phenotypic HSCs from bone marrow were sorted into Trizol and RNA was
extracted based on manufacturer’s protocol. Fragments were sequenced on a NovaSeq 6000 S4
(Illumina) with paired reads extending 150 bp. Sequence data were trimmed, aligned and analyzed
by Genome Technology Access Center in the Department of Genetics at Washington University
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School of Medicine. Gene expression heatmaps were generated using log2 transformed RPKM of
gene expression data by Heatmapper262.

2.2.6 Statistical analysis
Unpaired t-test was used to evaluate the significance of differences between two groups.
One-way ANOVA was used to evaluate the significance of differences between mutiple groups.
Two-way ANOVA was used to evaluate the significance of differences between two groups over
a period of time. All data are presented as mean ± SEM.

3.3 Results
3.3.1 Jak2 mutant HSPCs are less reactive to TGF-b stimulation in vitro
To determine whether Jak2 mutant HSPCs are less sensitive to TGF-b stimulation, we
treated freshly isolated bone marrow cells from wild type or Mx1-Cre; Jak2V617F mice with TGFb1 in vitro and measured the phosphorylation of Smad2/3 by flow cytometry. TGF-b1 induced
robust elevation of Smad2/3 phosphorylation in wild type phenotypic HSCs (lin- c-Kit+ Sca-1+
CD48- CD150+). However, induction of Smad2/3 phosphorylation was barely detected in HSCs
from Jak2V617F mice (Fig. 3.1A). Interestingly, as the cells mature, the sensitivity to TGF-b1
increases in Jak2 mutant cells. TGF-b1 induced modest induction of Smad2/3 phosphorylation in
Jak2V617F HSPCs (lin- c-Kit+ Sca-1-), which was still significantly reduced when comparing to wild
type HSPCs (Fig. 3.1B). Whereas, in lineage restricted myeloid progenitors (lin- c-Kit+), this
difference became minimal, with a similar induction of Smad2/3 phosphorylation by TGF-b1 in
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wild type and Jak2V617F cells (Fig. 3.1C). These data suggest that TGF-b signaling, at least
Smad2/3 phosphorylation, is selectively reduced in Jak2V617F HSCs but not lineage-restricted
progenitors.
We next attempted to determine if SMAD-independent non-canonical TGF-b signaling is
also affected in Jak2V617F HSPCs. However, we found that TGF-b1 stimulation in vitro was not
sufficient to induce detectable phosphorylation of Erk and p38, two of the MAP kinases in noncanonical TGF-b1 signaling, in wild type HSPCs (Fig. 3.1D-E). Therefore, the method is not
sensitive enough to determine if non-canonical TGF-b signaling is also altered in Jak2V617F HSPCs.

3.3.2 Loss of TGF-b signaling confers a fitness advantage to wild type but not
Jak2V617F HSCs
To further test the hypothesis that Jak2 mutant cells are less sensitive to the inhibitory
effect of TGF-b in vivo, competitive repopulation assays (CRAs) were performed using wild type
and Jak2V617F HSPCs in which Tgfbr2 was deleted to abrogate TGF-b signaling. We first
established bone marrow chimeras containing equal amounts of wild type and UBC-CreERT2;
Tgfbr2f/f HSPCs (hereafter referred to as TR2KO cells). Tamoxifen was given six weeks post
transplantation to activate Cre expression and delete Tgfbr2. Tgfbr2 deletion was confirmed in
bone marrow CD45+ leukocytes (Fig. 3.2A). Tgfbr2-deleted cells have a multilineage competitive
advantage when competing with wild type cells (Fig. 3.2B-D, black), suggesting that TGF-b
signaling negatively regulates HSPC repopulating activity. This is consistent with TGF-b’s known
role of suppressing HSPC growth. Next, we performed a similar experiment, competing Jak2V617F
cells to Jak2V617F; TR2KO cells (Fig. 3.2B-D, red). Surprisingly, no competitive advantage was
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observed with Jak2V617F; TR2KO cells. These data suggest that Jak2V617F HSPCs are
insensitive/resistant to the suppressive effect of TGF-b.

3.3.3 TGF-b confers a fitness advantage to Jak2V617F cells by selectively
inhibiting wild type HSCs
To extend these findings, CRAs were established that included the following 4 cohorts: 1)
wild type vs. Jak2V617F; 2) TR2KO vs. Jak2V617F; 3) TR2KO vs. Jak2V617F; TR2KO; and 4) wild type
vs. Jak2V617F; TR2KO (Fig. 3.3A). In each case, a 5:1 ratio of competitor to Jak2-mutated cells was
transplanted into lethally irradiated wild type recipients and tamoxifen was given six weeks after
transplantation to induce both Cre-mediated deletion of Tgfbr2 and activation of the Jak2V617F
allele. In cohort 1, as expected, when competing wild type to Jak2V617F cells, donor chimerism
with Jak2 mutated cells increased over time in myeloid lineages (Fig. 3.3A-E, black). Consistent
with this finding, Jak2 mutant chimerism in HSPCs and HSCs were also increased at 14 weeks
(Figure 3.3F, black). In cohort 2 (orange), the loss of TGF-b signaling in wild type HSPCs
completely abrogated the competitive advantage of Jak2V617F (Fig. 3.3A-E, orange). In fact, the
TR2KO cells outcompeted Jak2V617F HSPCs (Fig. 3.3F, orange). In cohort 3 (red), we asked whether
loss of TGF-b signaling in both wild type and Jak2V617F HSPCs could “level the playing field”.
Indeed, no expansion of Jak2 mutant peripheral blood leukocytes or HSPCs was observed in these
mice (Fig. 3.3A-F, red). Finally, in cohort 4 (blue), we observed that loss of TGF-b signaling only
in the Jak2 mutant cells had no impact on their repopulating activity (Fig. 3.3A-F, blue). The data
confirmed our hypothesis that Jak2V617F that elevated TGF-b selectively inhibits normal HSCs but
not Jak2V617F HSCs, providing a competitive advantage to Jak2 mutant cells.
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3.3.4 Cell cycle difference between wild type and Jak2V617F HSCs is TGF-b
dependent
As many previous studies have suggested that TGF-b promotes HSPCs quiescence, we
assessed the impact of TGF-b signaling on wild type and Jak2V617F HSPC cell cycle status in vivo.
We generated bone marrow chimeras containing 1) wild type vs. Jak2V617F; 2) TR2KO vs. Jak2V617F;
TR2KO or 3) TR2KO vs. Jak2V617F HSPCs. Of note, in all three of the bone marrow chimeras, the
presence of Jak2 mutant cells should increase the local level of endogenous TGF-b, reproducing
the microenvironment present in patients with MPNs. As expected, in the wild type vs. Jak2V617F
chimeras, the Jak2V617F HSPCs were less quiescent than wild type HSPCs, with a modest, but
significant decrease in cells in the G0 phase and an increase in cells in G1 phase (Fig. 3.4A-B,
black). Surprisingly, loss of TGF-b signaling resulted in a modest increase in quiescence of both
TR2KO and Jak2V617F TR2KO HSPCs. Of note, the loss of TGF-b signaling again “leveled the
playing field” with a similar percentage of quiescent TR2KO vs. Jak2V617F TR2KO HSCs (Fig. 3.4AB, red). Interestingly, when only deleting Tgfbr2 in wild type HSPCs but not Jak2V617F HSPCs,
both TR2KO and Jak2V617F HSPCs again had a slight increase and a comparable level of quiescence
(Fig. 3.4A-B, orange). This data is intriguing because whenever Tgfbr2 was deleted in the wild
type HSPCs, Jak2V617F HSPCs showed increased quiescence no matter its own Tgfbr2 status. This
raises the possibility for a non-cell intrinsic mechanism regulating the HSC quiescence. On the
other hand, these cell cycle changes were not observed in lineage restricted myeloid progenitors
(Fig. 3.4C). Jak2V617F myeloid progenitors had increased proliferation regardless of the presence
or absence of TGF-b signaling. This suggests that the effect of TGF-b on altering cell cycle of
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Jak2V617F cells is restricted to the HSPC population. Collectively, these data suggest that TGF-b
signaling negatively regulates HSC quiescence, affecting both wild type and Jak2V617F HSPCs.
Since the difference in cell cycle we observe is quite subtle, we assessed EdU (5-ethynyl2'-deoxyuridine) incorporation in the following bone marrow chimeras: 1) wild type vs. Jak2V617F;
and 2) TR2KO vs. Jak2V617F; TR2KO. Mice were analyzed 16 hours after a single dose of EdU. A
significant increase in EdU labeling was observed in Jak2V617F HSPCs, regardless of Tgfbr2 status
(Fig. 3.4D). The short-term nature of the EdU labeling is not optimal to assess HSPC quiescence.
Repeat experiments with prolonged, 10 days, EdU labeling are planned to provide a more
definitive understanding of the effects of TGF-b on the quiescence of wild type and Jak2V617F
HSPCs.

3.3.5 The suppressive effect of TGF-b1 on colony formation is comparable
between wild type and Jak2V617F HSCs
Numerous studies have shown that TGF-b inhibits colony formation and HSPC growth in
vitro. Thus, we next performed serial colony forming unit (CFU) plating assays in the presence or
absence of 10 ng/ml of TGF-b1. Similar to previous reports186-188, TGF-b1 inhibited colony
formation in CFU assay of wild type total bone marrow cells (Fig. 3.5A). Replating assays were
performed in the absence of continued TGF-b1 and showed that in wild type cultures, initial
exposure to TGF-b1 resulted in increased HSPC self-renewal (Fig. 3.4B). Interestingly, a similar
response to TGF-b1 was observed with Jak2V617F (Fig. 3.5A-B). Since the loss of SMAD2/3
phosphorylation was greatest in Jak2V617F HSCs (Fig. 3.1), we repeated the experiments using
sorted phenotypic HSCs. Surprisingly, colony forming ability of Jak2 mutated HSCs was still
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inhibited by TGF-b1 (Fig. 3.5C), and TGF-b1’s effect on self-renewal was also comparable
between wild type and Jak2V617F HSCs (Fig. 3.5D). Therefore, it is likely that TGF-b inhibits
colony formation and promotes self-renewal in a Smad2/3 independent manner.

3.3.6 Distinct changes in the transcriptome are induced by TGF-b1 in wild type
and Jak2V617F HSCs
To elucidate potential mechanisms responsible for the different response to TGF-b in wild
type and Jak2V617F HSCs in vivo, we performed transcriptome sequencing on sorted phenotypic
HSCs from wild type and Jak2V617F mice treated with vehicle alone or TGF-b1. Of note, we
confirmed successful induction of Smad2/3 phosphorylation in total bone marrow cells one hour
after TGF-b1 injection (Fig. 3.6A). Also, of note, no change in HSC number was observed in wild
type and Jak2V617F mice with this short-term TGF-b1 treatment (Fig. 3.6B). Principle component
analysis showed that HSCs from wild type mice treated with or without TGF-b1 clustered
independently; however, HSCs from Jak2V617F mice treated with or without TGF-b1 clustered
close to each other (Fig. 3.6C).
Consistent with our cell cycle analysis, which showed that loss of TGF-b1 signaling
induced HSC quiescence (Fig. 3.4A), TGF-b1 treatment in wild type mice induced expression of
cell cycle progression genes in HSCs, while down regulating cyclin-dependent kinase inhibitors
p19, p21 and p57 (Fig. 3.6D). Of note, this result is conflicting with prior studies showing that
treatment of HSPCs with TGF-b1 in vitro induces cyclin-dependent kinase inhibitors171,194-197.
Importantly, TGF-b1 induced changes in cell cycle genes are not found in HSCs from Jak2V617F
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mice (Fig. 3.6D), indicating that Jak2V617F HSCs are resistant to TGF-b’s effect on cell cycle
progression in vivo.
When looking at genes implicated in HSC self-renewal263-267, we observed that TGF-b1
induced self-renewal gene expression in wild type HSCs (Fig. 3.6E), which could explain
increased serial replating ability of cells exposed to TGF-b1 (Fig. 3.5B,D). While Jak2V617F HSCs
had similar response to TGF-b1 in serial replating assays, TGF-b1 did not induce this change in
gene expression in Jak2V617F HSCs (Fig. 3.6E). These contradictory results suggest that TGF-b1
may have very different effects in vitro and in vivo. Of note, these data were based on only two
biological replicates for each cohort. Studies are planned to repeat this experiment to generate four
mice per cohort.

3.4 Discussion
In this study, we tested the specific hypothesis that Jak2V617F MPN HSPCs are resistant to
the inhibitory effect of TGF-b and therefore gain fitness advantage. First, by detecting
phosphorylation of Smad2/3, we showed that Jak2V617F HSCs were not responsive to TGF-b1
stimulation while this phenotype was loss in lineage restricted progenitors. However,
unexpectedly, TGF-b1 still inhibited colony formation of sorted phenotypic HSCs from Jak2V617F
mice. This could be due to that the Alk1/Tgfbr2 signaling, which signals through Smad1/5/8173, or
the Smad-independent non-canonical signaling is intact in Jak2V617F HSCs and is contributing to
the growth inhibitory effect of TGF-b1. Based on online database BloodSpot268, Alk1 is expressed
at a significantly lower level comparing to Tgfbr1 (Alk5) in HSCs, indicating that Smad2/3 may
77

be the dominant canonical signaling in HSCs. Therefore, we attempted to measure multiple noncanonical signaling through flow cytometry; however, TGF-b1 was not sufficient to induce
detectable phosphorylation of at least Erk1/2 and p-38. Studies are underway to assess the impact
of treatment with inhibitors of non-canonical TGF-b signaling pathways on TGF-b induced growth
suppression in HSCs in vitro.
The role of TGF-b on HSCs in vivo is not yet well characterized due to conflicting results
from genetic mouse models. Deletion of Tgfbr1 did not have any effect on repopulating ability of
HSCs198 while deletion of Tgfbr299 and Smad4199 resulted in a repopulating disadvantage.
However, in our study, we found that deletion of Tgfbr2 actually had a competitive advantage
which contradicted what Yamazaki et al. had reported99. The conflicting results may be related to
differences in experimental design. In the Yamazaki study, pIpC was administered to Mx1-Cre;
Tgfbr2f/f mice two weeks prior to transplantation, raising the possibility that type I interferons
induced by pIpC may have an effect on HSC function, as reported previously269. Another
potentially important experimental difference is the timing of Tgfbr2 deletion. In the Yamazaki
paper, Tgfbr2 was deleted prior to competitive transplantation, whereas in our study, HSCs were
allowed to engraft for six weeks before Tgfbr2 deletion. We believe our approach may be a more
optimal way to assess repopulating ability under steady state conditions. Our data are consistent
with a recent report showing that HSCs exposed to TGF-b1 before transplantation had impaired
repopulating

ability202.

As

discussed

previously,

TGF-b

can

signal

through

both

Tgfbr1(Alk5)/Tgfbr2 or Alk1/Tgfbr2 receptors hetero-tetramers and transduce signals through
Smad2/3 or Smad1/5/8 respectively173. Deletion of Tgfbr1 may not disrupt all TGF-b signaling in
HSCs and this could be a reason why Larsson et al. observed a normal repopulating ability of
Tgfbr1 deficient cells198. Although Alk1 expression in HSCs is much lower than Alk5, Alk1/Tgfbr2
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signaling may still contribute to TGF-b’s effect on HSC repopulating ability. Altogether, our data
suggest that TGF-b signaling negatively regulates HSC repopulating activity.
Importantly, we found that while deletion of Tgfbr2 in wild type HSPCs resulted in
repopulating advantage, deletion of Tgfbr2 in Jak2V617F HSPCs did not affect its competitive
fitness. This data provide evidence that Jak2V617F HSPCs are resistant to TGF-b’s negative effect
on repopulating potential. These data are consistent with the observation that Jak2V617F HSPCs
show impaired SMAD2/3 phosphorylation. On the other hand, our CFU data suggest that Jak2V617F
HSPCs remain sensitive to the growth suppressive effect of TGF-b in vitro. Altogether, these
observations suggest the hypothesis that non-canonical signaling mediates the negative effect of
TGF-b on HSPC colony formation in vitro, while canonical, SMAD2/3-dependent signaling
mediates its in vivo effects on repopulating activity. Studies are planned to assess the impact of
inhibitors of non-canonical TGF-b signaling on colony formation.
Our competitive repopulation experiments showed that Jak2V617F HSPCs loss its fitness
advantage when competed with Tgfbr2-deleted HSPCs. These data suggest that increased TGF-b
expression in the bone marrow microenvironment contributes to the relative expansion of Jak2V617F
HSPCs by suppressing wild type HSPCs. In this model, increased local production of TGF-b by
Jak2V617F megakaryocytes generates a “toxic” microenvironment that selectively inhibits wild type
HSPCs. Experiments are planned to test this model by transplanting a small number of GFP labeled
Jak2V617F HSPCs into recipient mice and then using confocal imaging to determine whether there
are pockets of increased TGF-b expression and SMAD2/3 phosphorylation centered on Jak2V617F
megakaryocytes.
Currently, the widespread belief that TGF-b is a positive regulator of quiescence is mainly
based on in vitro data186-190, while its role on cell cycle in vivo is less clear. Studies abrogating
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TGF-b signaling in vivo by conditionally deleting Tgfbr1198 or Smad4199 both showed no changes
in cell cycle status in HSPCs. However, Challen et al. showed that treatment with TGF-b1 in vivo
induced proliferation of myeloid-biased HSCs while cell cycle in lymphoid biased HSCs was not
affected by TGF-b1 treatment201. Our cell cycle data suggest that loss of TGF-b results in a trend
to increased HSC quiescence. The RNA expression profiling data were consistent with this finding,
showing that TGF-b signaling in vivo induces the expression of cell cycle genes in wild type HSCs.
The impact of TGF-b signaling of Jak2V617F HSCs is less clear. A trend to increase quiescence was
observed in Jak2V617F HSCs after Tgfbr2 deletion. However, no change in cell cycle genes or shortterm EdU labeling were observed. To resolve this issue, we plan to repeat the EdU labeling
experiments using a longer (10 days) labeling time.
In recent years, studies have discovered that the commonly used HSC cell surface marker
Sca-1 is upregulated by interferon signaling270,271; thus, it may not be a proper phenotypic marker
to study HSCs in inflammatory conditions. Instead, EPCR (CD201) has been suggested as a more
consistently expressed marker on HSPCs272. Since Jak2 functions downstream of interferon
signaling, we checked if Jak2V617F altered Sca-1 expression on HSCs. However, we did not observe
significant changes in HSCs percentage measured by Sca-1 or EPCR (Fig. 3.7A-B). Therefore, we
confirm that our data regarding the definition of phenotypic HSCs population using regular SLAM
markers (lineage- c-Kit+ Sca-1+ CD48- CD150+) in Jak2V617F mice can be consider as appropriate.
Collectively, our data show that increased TGF-b expression in patients with MPNs
contributes to the clonal expansion of JAK2V617F HSCs by suppressing wild type HSCs. JAK2V617F
HSCs have attenuated canonical signaling in response to TGF-b. Ongoing studies are focused on
better defining the impact of TGF-b signaling on the proliferation and self-renewal capacity of
wild type and Jak2V617F HSCs.
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3.7 Figures

Figure 3.1. Jak2 mutant HSPCs are less reactive to TGF-b stimulation in vitro. (A-C) Mean
fluorescence intensity of Smad2/3 phosphorylation in HSCs (A), HSPCs (B) and lineage restricted
myeloid progenitors (MP) (C) from wild type (WT) or Jak2V617F mice. (D) Mean fluorescence
intensity of Erk1/2 phosphorylation in wild type HSPCs using SCF and GCSF stimulation as
positive controls. (E) Mean fluorescence intensity of p38 phosphorylation in wild type HSPCs
using Anisomycin stimulation as positive control. Data represent the mean ± SEM. *p<0.05,
***p<0.001, ****p<0.0001 by two-way ANOVA.
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Figure 3.2. Loss of TGF-b signaling confers a fitness advantage to wild type but not Jak2V617F
HSCs. (A) Tgfbr2 mRNA expression in bone marrow CD45+ leukocytes of WT: TR2KO and
Jak2V617F: Jak2V617F; TR2KO mix chimeras. (B-D) Chimerism of the TR2KO populations relative to
pre-tamoxifen treatment in peripheral blood leukocytes (PB) (B), neutrophils (PMN) (C) and B
cell (D) in 1 to 1 competitive repopulation of WT to TR2KO (black) or Jak2V617F to Jak2V617F; TR2KO
(red) bone marrow cells. WT: wildtype; TR2KO: UBC-CreERT2; Tgfbr2f/f. Data represent the mean
± SEM. *p<0.05, **p<0.01. The between-group difference was assessed using linear mixed
models to account for the correlation among measurements taken from the same mouse.
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Figure 3.3. TGF-b confers a fitness advantage to Jak2V617F cells by selectively inhibiting wild
type HSCs. (A-E) Jak2V617F chimerism relative to pre-tamoxifen treatment in total peripheral
blood leukocytes (PB) (A), neutrophils (PMN) (B), monocytes (C), B cells (D) and T cells (E). (F)
HSPCs and HSCs chimerism in the bone marrow 14 weeks post-tamoxifen. WT: wildtype; TR2KO:
UBC-CreERT2; Tgfbr2f/f. The gray bar indicates input total bone marrow percentage of Jak2V617F
cells. Data represent the mean ± SEM. Asterisks in (A-E) shows the significance comparing each
time point to base line in each group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Cross
shows between group differences: +++p<0.001, ++++p<0.0001. The over-time change and
between-group difference were assessed using linear mixed models to account for the correlation
among measurements taken from the same mouse.
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Figure 3.4. Cell cycle difference between wild type and Jak2V617F HSCs is TGF-b dependent.
(A-C) The distribution of cells in G0, G1 and G2M phases of cell cycle in HSCs (A), HSPCs (B),
and myeloid progenitors (MPs) (C) in mix bone marrow chimeras of wild type vs. Jak2V617F
(black), TR2KO vs. Jak2V617F; TR2KO (red) and TR2KO vs. Jak2V617F (orange). (D) Percentage of
EdU+ cells in each of the three stem and progenitor populations. The hollow bars represent the
non-Jak2 mutated populations while the slashed bars represent the Jak2 mutated populations. WT:
wildtype; TR2KO: UBC-CreERT2; Tgfbr2f/f. Data represent the mean ± SEM. *p<0.05, **p<0.01,
***p<0.001, and ****p<0.0001 by Student’s t-test or one-way ANOVA.
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Figure 3.5. The suppressive effect of TGF-b1 on colony formation is comparable between
wild type and Jak2V617F HSCs. (A) CFU of 20,000 total bone marrow cells from wild type (WT)
and Jak2V617F mice, with or without 10 ng/ml TGF-b1. (B) Serial replating of 20,000 cells from
previous plating. No TGF-b1 was added in 2nd to 4th plates. (C) CFU of 125 sorted phenotypic
HSCs from WT and Jak2V617F mice, with or without 10 ng/ml TGF-b1. (D) Serial replating of
10,000 cells from previous plating. No TGF-b1 was added in 2nd to 4th plates. Data represent the
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA.
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Figure 3.6. Distinct changes in the transcriptome are induced by TGF-b1 in wild type and
Jak2V617F HSCs. (A) Histogram of Smad2/3 phosphorylation in total bone marrow cells from wild
type mice treated with or without 2 µg of TGF-b1 for one hour. (B) Percentage of phenotypic
HSCs in c-Kit enriched populations. (C) Principle component analysis of RNA-sequencing results.
(D, E) Heatmaps of cell cycle (D) and self-renewal (E) regulating genes. Data represent the mean
of n=2 for each group.
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Figure 3.7. Phenotypic HSCs marker Sca-1 expression is not altered in Jak2V617F mice. (A)
Representative flow cytometry plots showing the gating of lineage- c-Kit+ EPCR+ CD48- CD150+
(E-SLAM) and lineage- c-Kit+ Sca-1+ CD48- CD150+ (SLAM) in wild type (WT) and Jak2V617F
mice bone marrow cells. (B) Percentage of HSCs quantified by E-SLAM and SLAM markers of
HSCs.
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Chapter 4: Summary and Future Directions
The overarching goal of this work is to understand the role of TGF-b signaling in the
disease pathogenesis of MPNs. In chapter 2, we demonstrated that TGF-b signaling in
mesenchymal stromal cells is essential for the development of myelofibrosis. Importantly, we
identify that TGF-b induces fibrosis through SMAD4-independent non-canonical JNK signaling.
In chapter 3, we provided evidence that TGF-b signaling in HSCs contributes to clonal expansion
by inhibiting normal HSCs. Together, this work offers a comprehensive analysis on how a single
cytokine, TGF-b, produced by malignant hematopoietic cells, contributes to MPN disease
pathogenesis through different mechanisms. It can not only act on the mesenchymal stromal
compartment to change the bone marrow microenvironment and increase disease severity, but it
also acts on HSPCs to promote clonal expansion. Therefore, targeting TGF-b signaling might be
beneficial for both severe MPN cases with myelofibrosis and early MPN cases or even JAK2
mutated clonal hematopoiesis.
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4.1 TGF-b Signaling in Mesenchymal Stromal Cells
Contributes to Myelofibrosis Through Non-canonical JNK
Signaling
4.1.1 Summary
In chapter 2, we utilized two MPN mouse models, carrying two mutations found in MPN
patients (Jak2V617F and MPLW515L) in a conditional stromal Tgfbr2 deletion model to demonstrate
that TGF-b signaling in the mesenchymal stromal compartment is essential for the development
of myelofibrosis. However, the change in bone metabolism in MPLW515L induced MPN is not
dependent on stromal TGF-b signaling. We also identify that TGF-b signaling in osteolineage cells
are dispensable for myelofibrosis, suggesting that the perivascular stromal compartments are the
major contributors of TGF-b induced bone marrow fibrosis. Importantly, we find that TGF-b
contributes to myelofibrosis through Smad4 independent non-canonical JNK pathway. Targeting
TGF-b signaling or the JNK signaling pathway may be beneficial to treat patients with
myelofibrosis.

4.1.2 The controversy on the cell of origin of myelofibrosis
The cell of origin of the fibrotic tissue in the bone marrow remains controversial, with
evidence suggesting mesenchymal stromal cells, monocyte derived fibrocytes and endothelial cells
are the potential origin. Using genetic mouse models of MPNs in reporter mice of mesenchymal
stromal cells123,124, studies have provided proof of principle evidence that the mesenchymal
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stromal populations are fibrogenic. However, others have suggested that monocyte-derived
fibrocytes and endothelial cells are the origin. While these data were mainly based on marker
expression instead of definitive proof, we cannot rule out the possibility that these cell types could
also be contributing to myelofibrosis. Nevertheless, no study has examined the mechanisms on
how these cells types contribute to the development of fibrosis. It would be important to test if
TGF-b or other pro-fibrotic factors acts on fibrocytes or endothelial cells to induce fibrosis. Based
on online gene expression datasets, BloodSpot and NichExplorer, Tgfbr1 and Tgfbr2 are both
expressed in monocytes and endothelial cells. Inducing myelofibrosis in models that genetically
delete Tgfbr2 in myeloid lineage cells (LysM-Cre) or vasculature (Cdh5-Cre) would be proof of
principle experiments to understand whether elevated TGF-b in MPNs can act on these other cell
types to facilitate myelofibrosis development.

4.1.3 The controversy on fibrosis inducing signals
Elevated inflammatory cytokines in MPNs have been suggested to promote bone marrow
fibrosis in patients. However, whether a specific factor is the master regulator, or multiple factors
work together to contribute to the development of myelofibrosis is not well understood. TGF-b
has always been known as a pro-fibrotic factor not only in the bone marrow but also other solid
organs273. Although previous studies and our data provided strong evidence that TGF-b signaling
in mesenchymal stromal cells is essential for the development of myelofibrosis, there are reports
suggesting other factors are the key contributors, including PDGF123, CXCL4124,125 and IL-6125.
Understanding whether these factors contribute to the formation of myelofibrosis through a
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cooperative manner or a sequential manner may help provide more knowledge on this complicated
disease.
While we identified that TGF-b contributes to myelofibrosis through the non-canonical
JNK signaling, PDGF also can activate JNK signaling259. Using genetic mouse models to
conditional delete JNK1/2 (JNK3 is not expressed in stromal populations) in mesenchymal
population may answer the question whether JNK is the main pathway that is driving
myelofibrosis. The receptors for CXCL4 and IL-6 are not expressed in the stromal populations in
the bone marrow. Therefore, their pro-fibrotic ability should function on the stromal populations
indirectly. It would be interesting to examine whether TGF-b acts downstream of these factors.
Indeed, one prior study found that when Cxcl4 was deleted from megakaryocytes, TPO
overexpression no longer led to elevated TGF-b expression125. Additional studies could be
performed to access if Cxcl4-/- and Il6-/- megakaryocytes from MPLW515L and Jak2V617F MPN mice
no longer have elevated TGF-b expression. If these inflammatory cytokines work in a sequential
manner in inducing fibrosis, targeting the further downstream signaling could be a better and more
specific way to tackle this disease.

4.1.4 SMAD4-dependent and -independent signaling in myelofibrosis
Using both genetic mouse models and cultured MSCs, we identified that TGF-b induced
myelofibrosis is, surprisingly, Smad4 independent. Instead, we showed that it is JNK signaling
that mediates this phenotype. Prior studies on the roles of TGF-b in the pathogenesis of fibrosis in
various diseases have provided evidence that both SMAD-dependent274 and SMAD-independent
non-canonical signaling, including activation of JNK275-277, p38278, PI3K/AKT279, or FAK280 can
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contribute to TGF-b’s pro-fibrotic effect. While our data suggest that JNK signaling is the critical
downstream signaling of TGF-b that is responsible for the development of myelofibrosis, targeting
JNK signaling can be challenging in patients because JNKs are known to play important roles in
controlling apoptosis as well as survival and proliferation of cells281. There are three JNK proteins
in humans, JNK1, JNK2 and JNK3. JNK1 and JNK2 are believed to be expressed in every cell
type, while JNK3 is specifically expressed in the brain, heart and testis281. Conflicting data has
suggested that JNK1 and JNK2 have overlapping and redundant functions or have distinct roles in
regulating cell growth in fibroblasts281. Understanding whether JNK1 and JNK2 function
differently in the mesenchymal stromal cells in regulating fibrosis phenotype would help narrow
down the best target for treating myelofibrosis. Currently, there are no specific inhibitors targeting
individual JNKs, so only genetic deletion approach is feasible in examining this question. Both
JNK1282 and JNK2283 knockout mice are viable and normal in size with modest T cell
differentiation deficiencies. Primary MSC cultures generated from these mice can be used to
access whether deletion of only either one of them can abrogate the TGF-b induced fibrosis
phenotypes. Using in vivo approach to transplant MPLW515L or Jak2V617F cells into JNK1-/- or JNK2/-

mice would also help elucidate whether abrogating one of them is sufficient to prevent fibrosis.

Targeting only one JNK protein would significantly reduce toxicity and potentially prevent the
serious adverse events found in clinical trials of a pan-JNK inhibitor (NCT01203943).
Furthermore, understanding how JNK signaling contributes to myelofibrosis would also
benefit better therapeutic development. It would be important to know if the major activator
protein-1 (AP-1) components targeted by JNK, including c-Jun, JunD, and activating transcription
factor 2 (ATF2)281, can directly regulate fibrosis gene expression. These transcription factors have
all been indicated to contribute to fibrosis256,284,285. Utilizing chromatin immunoprecipitation
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(ChIP) qPCR or ChIP-seq of these JNK regulated transcription factors would provide evidence on
whether fibrosis genes are direct targets of JNK signaling. In addition, RNA-sequencing of stromal
populations from patients with MPNs may identify relevant targets genes.

4.1.5 Alterations of bone metabolisms in MPNs
While changes in bone metabolism have been identified in patients with MPNs, not much
is known regarding mechanisms by which mutations in hematopoietic cells lead to osteosclerosis.
We predicted that TGF-b signaling in osteoblast lineage cells likely mediates this phenotype.
However, in contrast to myelofibrosis, abrogating TGF-b signaling in mesenchymal stromal cells
had no effect on the development of osteosclerosis. Impaired osteoclast function is a known cause
of osteosclerosis. However, in the MPLW515L MPN model, TRAP+ osteoclasts in the bone marrow
are increased. Studies are underway to assess osteoclast function by measuring serum levels of Cterminal telopeptide, which directly correlates with osteoclast activity. Of note, Chagraoui et al.
showed that global loss of TGF-b signaling prevented the development of osteosclerosis in their
TPO-overexpression model of MPN119. Although the data supporting this claim were limited (a
single image of a bone section), if true, this observation would suggest that TGF-b signaling in
osteoclasts may suppress their bone resorbing activity. Prior studies on the role of TGF-b in the
regulation of osteoclast development and activation are complex and controversial, with data
suggesting TGF-b can inhibit286-288 or promote287,289 osteoclasts function. To address this issue, an
osteoclast-specific Cre-transgene, such as Ctsk-Cre290, could be used to delete Tgfbr2 and abrogate
TGF-b signaling in osteoclasts in the MPLW515L mouse model of MPN.
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4.2 TGF-b Signaling Contributes to the Clonal Dominance
of JAK2 Mutant Hematopoietic Stem Cells
4.2.1 Summary
In chapter 3, we discovered that TGF-b contributes to the pathogenesis of MPNs, not only
by promoting the development of myelofibrosis, but also by contributing to the clonal expansion
of Jak2V617F HSPCs. We first showed that TGF-b induced Smad2/3 phosphorylation was
selectively loss in Jak2V617F HSPCs in vitro. Using multiple CRAs, we further confirmed that
Jak2V617F HSPCs are less responsive to the growth suppressive effect of TGF-b in vivo. Therefore,
in a microenvironment with elevated TGF-b, Jak2V617F HSCs gain a fitness advantage over wild
type HSCs. Surprisingly, we found that TGF-b’s suppressive effect on colony formation is intact
in Jak2V617F HSCs, suggesting that Samd2/3 independent non-canonical signaling may mediate
this phenotype. Cell cycle analysis along with transcriptome analysis revealed that TGF-b can
potentially stimulate cell cycle progression in vivo, which is opposite to its originally believed role
of stimulating quiescence in vitro. In addition, TGF-b’s effect on cell cycle could possibly be noncell intrinsic, which contributes to the difference in quiescence between wild type and Jak2V617F
HSCs.

4.2.2 Effects of non-canonical TGF-b signaling on colony formation
Despite markedly reduced TGF-b-induced SMAD2/3 phosphorylation, TGF-b1-induced
suppression of colony formation was intact in Jak2V617F HSCs. These divergent observations
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strongly suggest that non-canonical TGF-b signaling mediates HSC growth suppression in vitro.
To test this hypothesis, we plan to examine if inhibitors of individual non-canonical signaling
pathways, including MEK/ERK, JNK, p38, NFkB, PI3K/AKT, can block the ability of TGF-b to
suppress colony formation of sorted wild type HSCs. In addition to the SMAD2/3, TGF-b can
signal through ALK1/TGFbR2 heterodimers to activate SMAD1/5/8. Thus, we also plan to study
TGF-b-induced SMAD1/5/8 phosphorylation in Jak2V617F HSPCs.

4.2.3 Alternative methods to perform cell cycle analysis
Our cell cycle data suggest that TGF-b signaling negatively regulates HSC quiescence,
regardless of Jak2V617F status. However, the differences were small, and of borderline statistical
significance. We also used short term labeling with EdU to assess HSC proliferation. These data
suggested that Jak2V617F HSCs were more proliferative than wild type HSCs. However, loss of
TGF-b signaling had little impact on the percentage of EdU-labeled wild type or Jak2V617F HSCs.
There are more robust methods to quantify HSC quiescence, in which HSCs are uniformly labeled
and then followed for a long time to measure the progressive loss of label with successive cell
divisions. Common approaches include prolonged labeling with BrdU or EdU or the use of
inducible H2B-GFP to label cells. A chase of more than 70 days is required to effectively detect
the label retaining quiescent HSC populations291. However, these methods are not suitable for our
model, since deletion of Tgfbr2 is associated with the development of a lymphoproliferative
disorder after 2-3 months. Of note, previous studies have suggested that 10 days of BrdU labeling
results in 45-90% of HSC being labeled292,293. Therefore, we propose to treat mice for 10 days with
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EdU to label the bulk of non-quiescent HSCs and access if TGF-b signaling affects the amount of
non-labeled quiescent HSCs in our mix bone marrow chimera models.

4.2.4 Deciphering the mechanisms by which JAK2 mutation are resistant to
TGF-b
Our data provide strong evidence that JAK2V617F’s resistance to TGF-b contributes to its
clonal expansion. Examining how JAK2 mutation gain resistance to TGF-b is essential to further
understand MPN disease progression. Based on published literatures, there are several potential
mechanisms. One of them is that JAK2 mutated cells may have reduced TGF-b receptor expression.
However, RNA expression of Tgfbr1 and Tgfbr2 as well as Acvrl1 (Alk1) are comparable or even
higher in sorted HSCs from Jak2V617F comparing to wild type mice (Fig. 4.1A-C). Although
measuring cell surface protein expression of these receptors is needed, these data suggest that TGFb receptor expression likely does not account for the reduced response of Jak2V617F HSCs to TGFb. Another possible mechanism is that mutated JAK2 inhibits TGF-b signaling downstream of the
receptors in the malignant clone. Prior studies suggested that activated JAK-STAT signaling could
inhibit TGF-b signaling by inducing SMAD7 expression207-209. SMAD7 is known to inhibit
canonical TGF-b signaling by preventing TGFbRI from phosphorylating R-SMADs and by
directly competing with SMAD4 for binding to R-SMADs177,178. Indeed, we observed a modest
increase in Smad7 mRNA expression in Jak2V617F HSCs compared to wild type HSCs (Fig 4.1 DE). These data need to be confirmed with additional biologic replicates. We also plan to assess
SMAD7 expression by immunoblotting in purified LSK cells. If increased expression is confirmed,
we would use a genetic approach to assess the impact of Smad7 knock-down on the sensitivity of
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Jak2V617F HSPCs to TGF-b. Specifically, we would transduce Jak2V617F HSPCs with lentivirus
expressing shRNAs to Smad7 and transplant them into recipient mice and access the repopulating
potential. Smad2/3 phosphorylation in response to TGF-b would be assessed in Jak2V617F HSPCs
with or without Smad7 knock-down.

4.2.5 Investigating how Jak2 mutation alters TGF-b induced cell cycle
Our cell cycle analysis data provide intriguing result suggesting that TGF-b may be
actually inducing proliferation rather than quiescence in vivo. More interestingly, deletion of
Tgfbr2 in wild type cells alone can also induce quiescence in Jak2V617F HSCs with intact TGF-b
signaling. While it is essential to confirm this finding with the different strategy to access cell cycle
as discussed earlier, how TGF-b functions in a non-cell intrinsic manner to regulate cell cycle is
an important question to understand. Transcriptome analysis on Tgfbr2 deleted different
hematopoietic populations could be performed to access potential secreted factor(s) regulated by
TGF-b that may contribute to cell cycle regulation.

4.2.6 TGF-b’s different functions on lineage-biased HSCs
One previous report demonstrated that TGF-b has opposite functions on lymphoid-biased
and myeloid-biased HSCs201. Using side population to distinguish lymphoid and myeloid-biased
HSCs, Challen et al. showed that TGF-b inhibited the proliferation of lymphoid-biased HSCs
while promoting myeloid-biased HSCs proliferation. Therefore, Jak2V617F HSCs could react to
TGF-b differently than wild type HSCs due to that it is more myeloid-biased. Indeed, we found
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that Jak2V617F HSCs have increased expression of published myeloid-biased markers294-296 and
decreased expression of lymphoid-biased marker297 (Fig. 4.2). Although Jak2V617F HSCs do not
have different response to TGF-b in in vitro CFU assay, this lineage-biased difference may
contribute to HSCs sensitivity to TGF-b induction of Smad2/3 phosphorylation, and TGF-b’s role
in repopulating ability in vivo. Testing whether myeloid-biased HSCs have reduced Smad2/3
phosphorylation upon TGF-b stimulation may provide evidence that lineage potential can affect
cells’ reaction to TGF-b and contributes to Jak2V617F’s different response to TGF-b. We have
attempted to use CD229- as a myeloid-biased HSC marker. However, we were unable to define
the positive and negative populations using the only CD229 antibody that was commercially
available. Recently, Neogenin-1 (Neo1) has been reported as a novel surface marker for myeloidbiased HSCs296. We plan to utilize this new marker in the Smad2/3 phosphorylation assay to test
if Neo1+ HSCs are less responsive to TGF-b.

4.2.7 Imaging the malignant niche in Jak2V617F MPNs in mice
Based on our findings in chapter 3, we propose a model in which Jak2V617F hematopoietic
cells (likely megakaryocytes) express high levels of TGF-b, generating a localized
microenvironment that is selectively “toxic” to wild type HSCs. Specifically, any wild type HSCs
present in this localized region would be repressed, allowing for the expansion of Jak2V617F HSCs.
In this way, the clonal expansion of Jak2V617F HSCs might be propagated by serial development
of localized pockets of increased TGF-b expression. To test this model, we propose to use
multiplex confocal imaging to confirm the presence of localized pockets of TGF-b and TGF-b
signaling. Specifically, we have been breeding Jak2V617F mice with UBC-GFP reporter mice in
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order to track the mutant cells in the bone marrow. We will generate bone marrow chimera
reconstituted with a small number of Jak2V617F-GFP cells to model early stages of clonal
hematopoiesis/MPN (a 1:40 ratio of mutant to wild type bone marrow cells will be used). After
engraftment (~ 6 weeks), long bone sections will be imaged to detect, megakaryocytes, TGF-b1,
p-Smad2/3, GFP, and HSPC markers. Although this could be done using the Codex multiplex
imaging platform using a single panel of antibodies, we propose to use traditional confocal imaging
with four markers per tissue section. We predict that increased expression of TGF-b1 will be
present in mutant (GFP+) but not wild type megakaryocytes. We also predict that increased
Smad2/3 phosphorylation will be present in cells surrounding the mutant megakaryocytes. Finally,
we predict that relative to wild type HSPCs, there will be a relative accumulation of mutant HSPCs
in regions surrounding the mutant megakaryocytes.

4.2.8 Targeting TGF-b signaling in JAK2V617F clonal hematopoiesis and MPNs
Clonal hematopoiesis (CHIP) not only highly increases the risk of developing
hematopoietic malignancies, the risk of developing coronary heart disease and venous thrombosis
is 12-fold higher in individuals with CHIP due to JAK2 mutations, which is the highest and most
significant among all CHIP mutations225. Therefore, preventing clonal expansion and progression
of JAK2V617F CHIP to malignancies or cardiovascular events has significant clinical benefits. Since
we have identified that TGF-b contributes to the clonal expansion of Jak2V617F HSPCs, it would
be interesting to know if individuals with clonal hematopoiesis carrying JAK2 mutations also have
elevated TGF-b. If the low percentage of mutant cells are not enough to induce a detectable bulk
elevation, using similar imaging studies as described in the previous section might provide
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evidence of local TGF-b elevation in JAK2 mutated cells. However, it is not feasible to label
mutant cells with fluorescence reporters in human specimens. Therefore, detecting mutant cells
would be more challenging in bone marrow samples from individuals with CHIP. Since JAK2V617F
leads to constitutive activation of the JAK/STAT signaling, staining for phosphorylated STAT3/5
proteins could be a potential way of detecting cells with JAK2V617F mutation. If STAT3/5
phosphorylation is measurable, imaging individuals with CHIP carrying JAK2 mutations would
provide a better rationale of targeting TGF-b signaling in JAK2V617F CHIP.
Multiple drugs targeting TGF-b signaling have been on clinical trials for different
malignancies, including inhibitors for TGFbR1, LY2157299, (NCT01246986, NCT01373164)
and ligand trap for TGF-b1, AVID200, (NCT03895112, NCT03834662). This provide strong
feasibility of applying these already available therapeutic agents to treat MPN patients early in the
course of disease and also individuals with CHIP in JAK2 mutations. The existing treatment for
MPNs are mainly focusing on targeting the malignant clone. Combining treatments targeting the
malignant cells as well as the malignant niche may potentially increase the effectiveness of tackling
these diseases.
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4.3 Figures

Figure 4.1. Expression of TGF-b receptors and Smad7 in wild type and Jak2V617F HSCs. (AD) mRNA expression of Tgfbr1 (Alk5) (A), Tgfbr2 (B), Acvrl1 (Alk1) (C) and Smad7 (D) accessed
by RNA-sequencing of sorted phenotypic HSCs from wild type (WT) and Jak2V617F mice. (E)
mRNA expression of Smad7 relative to Actb measured by qRT-PCR.
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Figure 4.2. Jak2V617F HSCs have a myeloid-biased gene expression signature. (A-B) mRNA
expression of lymphoid-biased HSC marker CD229 (A) and myeloid-biased markers Neo1, CD41,
Anxa7, Ap3b1 and Arhgef12 (B) measured by RNA-sequencing in sorted wild type (WT) and
Jak2V617F phenotypic HSCs.
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